Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 1 of 90  
  
 
 
 
 
 
 
 
  
Early  Feasibility Study  of the Edwards  
FORMA Tricuspid Transcatheter Repair System  
 
 
CLINICAL PROTOCOL  
(Clinical Investigational Plan)  
 
 
Study Number:  2014 -04 
Version :  K 
Effective Date:  February 8, 2018  
 
 
CONFIDENTIAL  
 
Study Sponsor:  
Edwards Lifesciences LLC  
One Edwards Way  
Irvine, CA [ZIP_CODE] [LOCATION_003]  
 
 
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 2 of 90  
 TABLE OF CONTENTS  
SYNOPSIS  ................................ ................................ ................................ ................................ .................  5 
1 INTRODUCTION  ................................ ................................ ................................ ............................  10 
1.1 CLINICAL BACKGROUND  ................................ ................................ ................................ ......................  10 
1.1.1  Disease Process  ................................ ................................ ................................ .....................  10 
1.1.2  Etiology  ................................ ................................ ................................ ................................ .. 10 
1.2 ALTERNATIV E TREATMENT /THERAPI[INVESTIGATOR_5165]  ................................ ................................ ................................ ... 12 
1.2.1  Surgical Tricuspid Valve Intervention  ................................ ................................ ....................  12 
1.2.2  Medical Therapy  ................................ ................................ ................................ ....................  13 
1.2.3  Percutaneous Tricuspid Valve Repair  ................................ ................................ ....................  13 
1.2.4  Transcatheter Tricuspid Valve Replacement  ................................ ................................ .........  13 
2 STUDY PURPOSE  ................................ ................................ ................................ ...........................  13 
2.1 INTENDED USE ................................ ................................ ................................ ................................ .. 14 
2.2 PRIOR TESTING  ................................ ................................ ................................ ................................ . 14 
2.3 CLINICAL EXPERIENCE  ................................ ................................ ................................ .........................  14 
2.4 STUDY DEVICE  ................................ ................................ ................................ ................................ .. 18 
2.4.1  General Device Description and Components  ................................ ................................ .......  18 
2.4.2  Edwards FORMA Tricuspid Transcatheter Spacer System  ................................ .....................  18 
2.4.3  Access Sheaths  ................................ ................................ ................................ ......................  21 
2.4.4  Edwards FORMA Tricuspid Transcatheter Railing Delivery System  ................................ .......  23 
2.4.5  Edwards FORMA Tricuspid Transcatheter Retrieval System  ................................ .................  24 
3 RISK ANALYSIS  ................................ ................................ ................................ ..............................  24 
3.1 POTENTIAL RISKS ................................ ................................ ................................ ...............................  24 
3.2 RISK MANAGEMENT  ................................ ................................ ................................ ..........................  27 
3.3 BENEFITS  ................................ ................................ ................................ ................................ .........  27 
3.4 JUSTIFICATION  ................................ ................................ ................................ ................................ .. 28 
4 STUDY OBJECTIVES  ................................ ................................ ................................ .......................  28 
5 STUDY ENDPOINTS ................................ ................................ ................................ ........................  28 
5.1 FEASIBILITY ENDPOINTS  ................................ ................................ ................................ ......................  28 
5.1.1 Safety Endpoint  ................................ ................................ ................................ .....................  28 
5.1.2  Performance Endpoint  ................................ ................................ ................................ ...........  28 
6 STUDY DESIGN  ................................ ................................ ................................ ..............................  29 
7 PATIENT POPULATION  ................................ ................................ ................................ ..................  29 
7.1 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS ................................ ................................ ......................  29 
7.2 INCLUSION CRITERIA  ................................ ................................ ................................ ..........................  29 
7.3 EXCLUSION CRITERIA  ................................ ................................ ................................ ..........................  30 
8 PROCEDURES AND METHODS  ................................ ................................ ................................ .......  32 
8.1 INFORMED CONSENT  ................................ ................................ ................................ ..........................  32 
8.2 PATIENT ENROLLMENT  ................................ ................................ ................................ .......................  32 
8.3 BASELINE EVALUATION  ................................ ................................ ................................ .......................  33 
8.4 ANTIPLATELET / ANTICOAGULATION THERAPY  ................................ ................................ .........................  36 
8.5 DEVICE PREPARATION  ................................ ................................ ................................ ........................  37 
8.6 IMPLANT PROCEDURE  ................................ ................................ ................................ ........................  37 
8.6.1  Antibiotic Prophylaxis  ................................ ................................ ................................ ............  38 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #[ADDRESS_934395] -Implant  ................................ ................................ ................................ ................  39 
8.6.4  Discharge  ................................ ................................ ................................ ...............................  39 
8.7 FOLLOW UP VISITS ................................ ................................ ................................ ............................  40 
8.7.1  Follow Up Visit Windows  ................................ ................................ ................................ .......  41 
8.8 MISSED PATIENT VISITS ................................ ................................ ................................ ......................  44 
8.9 WITHDRAWAL CRITERIA AND PROCEDURES  ................................ ................................ ............................  44 
8.10 PATIENT STUDY COMPLETION  ................................ ................................ ................................ ..............  45 
9 TRAINING  ................................ ................................ ................................ ................................ ...... 45 
9.1 INVESTIGATORS DEVICE TRAINING  ................................ ................................ ................................ ........  45 
9.2 TRAINING OF INVESTIGATIONAL SITE PERSONNEL  ................................ ................................ .....................  45 
9.3 TRAINING DOCUMENTATION  ................................ ................................ ................................ ...............  46 
10 INVESTIGATIONAL DEVICE MANAGEMENT  ................................ ................................ ...................  46 
10.1 DEVICE SHIPMENTS  ................................ ................................ ................................ ............................  46 
10.2 DEVICE ACCOUNTABILITY  ................................ ................................ ................................ ....................  46 
10.3 DEVICE STORAGE  ................................ ................................ ................................ ...............................  46 
10.4 DEVICE RETURN  ................................ ................................ ................................ ................................  47 
11 DATA COLLECTION AND REPORTING  ................................ ................................ .............................  47 
11.1 DATA COLLECTION METHODS  ................................ ................................ ................................ ..............  47 
11.2 CASE REPORT FORMS  ................................ ................................ ................................ .........................  47 
11.3 SOURCE DOCUMENTATION REQUIREMENTS  ................................ ................................ ............................  48 
11.4 QUALITY CONTROL AND QUALITY ASSURANCE PROCEDURES  ................................ ................................ ...... 48 
12 REPORTABLE EVENTS / EFFECTS  ................................ ................................ ................................ .... [ADDRESS_934396]  ................................ ................................ ........  50 
12.1.6  Device Deficiency and Malfunction  ................................ ................................ .......................  50 
12.2 REPORTING PROCEDURE  ................................ ................................ ................................ .....................  51 
12.3 FINDINGS EXPECTED TO OCCUR WITH TREATMENT OF TRICUSPID REGURGITATION AND /OR INTERVENTIONAL CARDIAC 
PROCEDURES THAT DO NOT REQUIRE REPORTING TO THE SPONSO R ................................ ................................ .........  53 
12.4 DEATHS AND EXPLANTS  ................................ ................................ ................................ ......................  54 
12.4.1  Patient Deaths  ................................ ................................ ................................ .......................  54 
12.4.2  Device Explants  ................................ ................................ ................................ ......................  55 
13 STATISTICAL ANALYSIS  ................................ ................................ ................................ ..................  55 
13.1 SAMPLE SIZE ................................ ................................ ................................ ................................ .... 55 
13.2 ANALYSIS POPULATION  ................................ ................................ ................................ .......................  55 
13.3 DEVICE SUCCESS ENDPOINT ANALYSIS  ................................ ................................ ................................ ... 56 
13.4 PROCEDURE SUCCESS ENDPOINT ANALYSIS  ................................ ................................ .............................  56 
13.5 CLINICAL  SUCCESS ENDPOINT ANALYSIS ................................ ................................ ...............................  56 
13.6 ADDITIONAL SAFETY ANALYSIS  ................................ ................................ ................................ .............  57 
13.7 MISSING DATA ................................ ................................ ................................ ................................ . 57 
13.8 ANALYSIS SOFTWARE  ................................ ................................ ................................ .........................  57 
14 MONITORING  ................................ ................................ ................................ ...............................  57 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 4 of 90  
 14.1 MONITORING METHODS  ................................ ................................ ................................ ....................  57 
14.2 MONITORING PLAN ................................ ................................ ................................ ...........................  57 
14.3 PROTOCOL DEVIATION  ................................ ................................ ................................ .......................  58 
14.4 COMMUNICATION PROCEDURES  ................................ ................................ ................................ ...........  59 
15 DATA MONITORING COMMITTEE  ................................ ................................ ................................ . 59 
16 APPLICABLE REGULATIONS AND GUIDELINES  ................................ ................................ ...............  59 
16.1 DATA PROTECTION AND PATIENT CONFIDENTIALITY  ................................ ................................ .................  60 
16.2 INVESTIGATOR RESPONSIBILITIES  ................................ ................................ ................................ ..........  60 
16.2.1  General Duties  ................................ ................................ ................................ .......................  60 
16.2.2  Investigator Records  ................................ ................................ ................................ ..............  61 
16.2.3  Investigator Reports  ................................ ................................ ................................ ..............  61 
16.3 SPONSOR RESPONSIBILITIES  ................................ ................................ ................................ .................  62 
16.3.1  General Duties  ................................ ................................ ................................ .......................  62 
16.4 SELECTION OF INVESTIGATORS  ................................ ................................ ................................ .............  62 
16.4.1  Monitoring the Study  ................................ ................................ ................................ ............  62 
16.4.2  Sponsor Records  ................................ ................................ ................................ ....................  62 
16.4.3  Sponsor Reports  ................................ ................................ ................................ ....................  62 
16.5 STUDY CHANGES  ................................ ................................ ................................ ...............................  63 
16.6 STUDY COMPLETION OR TERMINATION AND CLOSE-OUT ................................ ................................ ..........  63 
16.7 AUDITS AND INSPECTIONS  ................................ ................................ ................................ ...................  64 
16.8 PUBLICATION POLICY  ................................ ................................ ................................ .........................  64 
17 REFERENCES  ................................ ................................ ................................ ................................ .. 65 
18 DEFINITIONS  ................................ ................................ ................................ ................................ . 66 
19 APPENDIX A - SAMPLE INFORMED CONSENT FORM  ................................ ................................ ..... 72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 5 of 90  
  
SYNOPSIS  
 
Study Number:  2014 -04  
Title:  Early Feasibility  Study of the Edwards FORMA Tricuspid Transcatheter 
Repair System  
Study  Sponsor 
Contacts:   
 
 
 
  
 
 
  
 
 
 
 
 
Study Principal 
Investigator:   
 
  
[INVESTIGATOR_688693]:  The objectives of this early feasibility  study are to:  
• Evaluate the safety and function of the Edwards FORMA  Tricuspid 
Transcatheter Repair System  
• Provide guidance for future clinical study designs utilizing the 
Edwards FORMA  Tricuspid Transcatheter Repair System  
• Provide guidance for future  Edwards FORMA  Tricuspid 
Transcatheter Repair System  development efforts  
Study Devi ces: The Edwards FORMA  Tricuspid Transcatheter Repair System : 
• Edwards FORMA Tricuspid  Transcatheter  Spacer  System, Model 
9900SS A  
• Edwards FORMA  Tricuspid Transcatheter Guide Sheath, Model 
9900GSA20  
• Edwards FORMA  Tricuspid Transcatheter Introducer Sheath , Model 
9900IS 20 
• Edwards FORMA Tricuspid  Transcatheter  Railing Delivery System, 
Model 9900DS A  
• Edwards FORMA  Tricuspid Transcatheter Retrieval System , Model 
9900RS A 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 6 of 90  
 Intended Use:  The Edwards FORMA  Tricuspid Transcatheter Repair System is intended 
for patients with tricuspid  regurgitation who are deemed to be 
candidates for transcatheter tricuspid valve repair with the Edwards 
FORMA Tricuspid Transcatheter Repair System by [CONTACT_407769]  
(a min imum of one cardiologist and one cardiac surgeon) .  
Study Design:  This is a multi -site, prospective, early feasibility  study. 60 patient s will be 
enrolled in the study.  All enrolled study patient s will be assessed for 
clinical follow -up at the following intervals:   [ADDRESS_934397] implant procedure.  
Study Duration:  Estimated Study Enrollment Start Date:  
Estimated Study Enrollment End Date:  
Estimated Study Follow Up Completion:  December  2015 
December  2018 
January  2022  
Study Population:  Adult patient s with clinically significant, symptomatic , functional, 
tricuspid regurgitation who are deemed to be candidates for 
transcatheter tricuspid valve repair by [CONTACT_407769]  (a minimum 
of one cardiologist and one cardiac surgeon) . 
Enrollment Criteria  
(Inclusion) : 1. Signed and dated IRB approved study consent form prior to  study 
related procedures  
2. ≥ eighteen ( 18) and ≤ eighty five  (85) years old   
3. Symptomatic  severe (Stage D)  functional , tricuspid  regurgitation 
(per applicable guidelines) requiring transcatheter tricuspid valve 
repair as assessed by [CONTACT_407769]  (a minimum of one 
cardiologist and one cardiac surgeon)  
4. Signs or symptoms of persistent right heart failure despi[INVESTIGATOR_688694]  
5. Willing to attend study follow -up assessments for up to 3 years  
Enrollment Criteria 
(Exclusion):  1. Tricuspid  valve /right heart anatomy not suitable for the study 
device :  
a. Native tricuspid  annulus area  < 2.63 cm2 (12 mm device) or < 
3.27cm2 (15 mm device)  as measured by [CONTACT_688719]  
b. Sub-valvular structures/anatomy that would preclude proper 
anchor  or Spacer  placement, positioning and retrieval  
c. Access pathway vessel diameter < 7.1 mm (Introducer 
Sheath ) or < 8.0 mm ( Guide Sheath ) 
2. Moderate or greater tricuspid  valve stenosis  
3. Tricuspid effective regurgitant orifce area (EROA)  EROA ≥ 1.0 cm2 
by [CONTACT_976][INVESTIGATOR_688695] ≥ 2.0 cm2 by 3D measurement  
4. Severe right ventric ular (RV) dysfunction as evidenced by [CONTACT_472571] < 
[ADDRESS_934398] 180 days, or that 
precludes proper placement of the device, or  may  interfere with 
the device , or presence of two or more RV leads  
6. RV lead  with pace maker dependency  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 7 of 90  
 7. Untreated clinically significant coronary artery disease requiring 
immediate revascularization  
8. Any therapeutic invasive cardiac procedure performed within 30 
days of the scheduled implant procedure  
9. Patients on chronic dialysis    
10. Patients with renal insufficiency ( estimated glomerular filtration 
rate ( eGFR ) < 30 mL/min/1.73 m2)  
11. Patients with chronic anemia (Hb <9  g/L)  
12. Patients with  thrombocytopenia (platelet count <100,000/mm3) 
13. Patients with  significant pericardial effusion  
14. Significant stenosis of the left subclavian vein that may preclude 
safe introduction of the delivery catheter  
15. Myocardial infarction or unstable angina within 30 days of 
scheduled implant procedure  
16. Hemodynamic instability or  on IV inotropes within 30 days of 
scheduled implant procedure  
17. Patient requiring surgery  under general anesthesia  for any reason 
within 30 days of scheduled implant procedure  
18. Severe left ventricular dysfunction with ejection fraction < 30% 
within 90 days  of scheduled implant procedure  
19. Patients with systolic pulmonary artery pressure > 60 mmHg  via 
transthoracic echocardiography  or right heart catheterization  
within 90 days  of scheduled implant procedure  
20. Patients with uncontrolled hypertension defined a s systolic blood 
pressure ( SBP) ≥ 180 mmHg or diastolic blood pressure ( DBP) ≥ 110 
mmHg  
21. Aortic, and/or pulmonic valve stenosis and/or regurgitation graded 
as moderate  or greater  
22. Mitral stenosis or regurgitation graded as severe  
23. Active endocarditis or infection within [ADDRESS_934399] (6MWT) < 150 m eters and > 400 meters within 
90 days of scheduled implant procedure  
26. Significant frailty  (i.e. Katz Index of Independe nce in Activities of 
Daily Living (ADL)  ≤ 2) within 90 days of scheduled implant 
procedure  
27. Chronic l iver disease with a MELD score  of 12 or greater  
28. Recurrent (>2 per 12 months) hospi[INVESTIGATOR_688696]  
29. Non -cardiac disease limiting life expectancy to be less than 12 
months at baseline evaluation  
30. Documented history of bleeding diathesis, coagulopat hy or 
gastrointestinal bleeding within 90 days  of scheduled implant 
procedure  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 8 of 90  
 31. Evidence of  left or  right sided intracardiac mass, thrombus, or 
vegetation  
32. Prior venous stent placed within the access route (e.g., sub -clavian 
vein)  that could negatively react with device  
33. Previous implantation of a bioprosthetic or mechanical  tricuspid 
valve  or a leaflet repair device  
34. Known hypersensitivity to cobalt chromium, nitinol or titanium  
35. Known hypersensitivity to anticoagulation therapy or contrast 
agent, which cannot be adequately medicated  
36. Patient is a current intravenous drug user  
37. Female of child -bearing potential is pregnant or lactating  
38. Patient is currently participating in another drug or device clinical 
study   
39. Patient requires emergent/emergency treatment for tricuspid 
insufficiency  
40. Patient is under guardianship  
Feasibility  
Endpoints:  Safety :  
Composite of major adverse events (MAE) defined as cardiovascular 
mortality, myocardial infarction, new need for renal replacement 
therapy, severe bleeding and re-intervention for study device related 
complications at 30 days.  
 
Performance : 
• Device success: device is deployed as intended and th e delivery 
system is successfully retrieved as intended at the time of the 
patient’s exit from the cardiac catheterization  laboratory.  
 
• Procedural success: device success with evidence of tricuspid  
regurgitation  (TR) reduction as evidenced by a relative reduction in 
EROA of ≥ 30% from baseline to discharge and without the need for 
a surgical or percutaneous intervention prior to hospi[INVESTIGATOR_2345].  
 
• Clinical success: procedural success without MAEs at  30 days.   
(MAEs: cardiovascular mortality, myocardial infarction, new need 
for renal replacement therapy, severe bleeding and re -intervention 
for study device related complications)  
Study Committee s: Independent Data Monitoring Committee ( DMC)   
 
The DMC will consist of a minimum of 3 members, all members being 
physicians; one cardiothoracic surgeon , one interventional cardiologist 
and one cardiologist  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 9 of 90  
 Echocardiography 
Core Laboratory:    
  
  
 
  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 10 of 90  
 1 INTRODUCTION  
1.1 CLINICAL BACKGROUND  
1.1.1 DISEASE PROCESS  
Tricuspid  Regurgitation ( TR), tricuspid  insufficiency or tricuspid  incompetence describes a 
condition in which blood flow through the tricuspid  valve flows in the incorrect direction 
during part of the cardiac cycle. Normally, during diastole, the tricuspid  valve opens as a 
result of atrial pressure from the right  atrium,  allowing blood to flow through the tricuspid  
valve, into the right  ventricle.  Diastole ends with atrial contraction and the tricuspid  valve 
closing to prevent a reversal of blood flow.  However, in patients with TR, the tricuspid  
valve is unable to form a tight seal at diastole end (when it should be closed), allowing 
blood to flow back into the right  atrium.  
 
Although TR often accompanies mitral or aortic valve disease, it is usually asymptomatic, 
traditionally considered less clinically significant, and left untreated.  This scenario where 
the tricuspid valve is left untreated has resulted in the tricuspid val ve being commonly 
referred to as the “forgotten” valve.  While trace to mild levels of TR are commonly found 
in a large number of patients without clinical consequence , moderate and severe levels 
can have detrimental effects on a patients quality of life [1]. Patients with severe TR 
usually present with signs or  symptoms of right heart failure ( HF), including peripheral 
edema  and ascites [2].  
1.1.[ADDRESS_934400] many underlying etiologies, but the majority of these can be divided into two 
major categories: degenerative and functional TR.  Degenerative (primary, organic or 
structural) TR refers to regurgitation resulting from disease processes affecting th e 
integrity of the tricuspid  valve leaflets and/or valve apparatus, such as in rheumatic heart 
disease, tricuspid  valve prolapse or endocarditis.  In contrast, functional (secondary or 
non-structural) TR refers to regurgitation occurring in the absence of significant structural 
disease of the tricuspid  valve and/or apparatus.  Functional TR occurs in approximately 
80% of cases of significant TR [2], resulting  from annular dilation and right ventricular 
enlargement, which is often secondary to left heart failure from myocardial or valvular 
causes, right ventricular volume and pressure overload, and dilation of cardiac chambers.  
Significant TR may be clinically silent for a prolonged period, during which time 
progressive right ventricle (RV) dilatation and dysfunction may develop, similar to 
changes that can occur with asymptomatic mitral regurgitation (MR) and its effect on LV 
function.  
 
 
 
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 11 of 90  
 Figure 1: Dilation of  the Tricuspid Annulus – Dreyfus et al. [3] 
 
 
Tricuspid regurgitation is a common echocardiographic finding that is often considered 
benign unless associated with significant pulmonary hypertension or RV or LV 
dysfunction. It has been shown that increasing TR severity is associated with worse 
survival  regardless of left ventricular ejection fraction  (LVEF ) or pulmonary artery 
pressure [1]. Severe TR is associated with a p oor prognosis, independent of age, 
biventricular systolic function, RV size, and IVC dilation [1]. 
 
Figure 2: Kaplan -Meier  survival curves for all patients with tricuspid regurgitation 
(TR). [1] 
 
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 12 of 90  
 1.2 ALTERNATIVE T REATMENT/T HERAPI[INVESTIGATOR_5165]  
1.2.1 SURGICAL TRICUSPID  VALVE INTERVENTION  
The decision as to treat TR has been controversial over the years, but has recently become 
recommended in symptomatic patients and in some cases asympto matic patients as 
prophylactic treatment at the time of MR surgery [4]. The decision as to whether repair or 
replacement is recommended is demonstrated in the diagram below.  
 
Figure 3 : 2014 AHA/ACC Indications for Tricuspid Surgery [2] 
 
 
 
Several techniques are available to correct functional tricuspid regurgitation. These 
include the stitch annuloplasty, such as semicircular (classical De Vega repair) or simple 
lateral annuloplasty (Kay), novel techniques such as edge -to-edge or clover technique and 
suture bicuspi[INVESTIGATOR_688697], use of flexible and rigid prosthetic rings or 3D rings, 
flexible prosthetic bands, and use of artificial chordae with polytetrafluoroethylene 
sutures for anterior and septal tricuspid l eaflet pathology. Whereas the short -term 
outcomes of these techniques are satisfactory, the majority are limited in the mid - and 
long term by [CONTACT_688720]/or recurrent regurgitation [5]. 
  
While repai r, specifically annuloplasty is considered the procedure of choice, if repair is 
not feasible or unsuccessful , replacement may be consider ed[6]. For replacement both 
bioprosthetic as well as mechanical valves provide viable options.  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #[ADDRESS_934401] developed. 
Additionally, medical therapi[INVESTIGATOR_688698]/or pulmonary resistance [2].  
For the patient population that would benefit from surgical intervention, but is 
characterized as high -risk or non -surgical, medical management is likely to only provide 
temporary symptom relief.  The lack of b enefit from medical therapi[INVESTIGATOR_688699].    
1.2.[ADDRESS_934402] due to the 
minimally invasive nature of the procedures , particularly since surgery in functional 
patients is only indicated when they are undergoing concominate valve surgery [2, 7].   
 
Percutaneous devices are being investigated  which mimic surgical repair techniques. 
These devices are targeted for patients who  are at high operative risk for surgery. These 
devices aim to approximate the leaflets by [CONTACT_688721], simulating a bicuspi[INVESTIGATOR_688700]. Another 
emerging technology is a device which uses pledgets in the annulus to reduce the size of 
the annulus.   
1.2.[ADDRESS_934403] the TR , it prevents back flow beyond the right atrium 
with the goal of reducing symptoms, normalizing liver function, a nd improving physical 
capacity.  
2 STUDY PURPOSE  
The early feasibility  study  of the Edwards FORMA  Tricuspid Transcatheter Repair System  
is a multi -site, prospective, early feasibility  study to evaluate the safety and  function of 
the Edwards FORMA  Tricuspid Transcatheter Repair System . 
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #[ADDRESS_934404], and one Cardiac Surgeon  
(herein after referred to as  the local Heart Team) . 
2.2 PRIOR TESTING  
A Report of Priors ( Clinical Investigator’s Brochure (CIB) ) has been prepared for the 
Edwards FORMA  Tricuspid Transcatheter Repair System .  This document  provides the 
prior testing conducted on the system components.  
2.3 CLINICAL EXPERIENCE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 15 of 90  
  
 
 
 
 
 
 
 
 
 
 
  
   
  
  
           
 
 
      
 
 
       
                 
                 
  
  
 
 
  
  
  
  
   
  
 
 
  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 16 of 90  
  
 
 
 
  
 
 
 
 
  
   
  
  
           
 
 
      
 
 
       
                 
                 
 
 
  
  
   
  
  
   
 
 
  
  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 17 of 90  
  
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 18 of 90  
 2.4 STUDY DEVICE  
2.4.1 GENERAL DEVICE DESCRIPTION AND COMPONENTS  
The Edwards FORMA  Tricuspid Transcatheter Repair System  (herein after referred to as 
the FORMA  System)  is comprised of five (5) different sub -systems as listed below (Table 
5).   A general device description will be provided for all components of the Edwards 
FORMA  System .  Further detailed information such as materials, manufacturing, testing, 
etc. however, will be provided in the Report of Priors ( Clinical Investigator’s Brochure 
(CIB) ).   
 
The following table includes the device names and model numbers of the components 
that make up the FORMA  System : 
 
Table 5 – Device Names and Model Numbers  
 
Product Name  [CONTACT_688750]     
2.4.2 EDWARDS FORMA  TRICUSPID  TRANSCATHETER  SPACER SYSTEM  
 
 
 
 
   
[IP_ADDRESS]  Spacer  Device  
 
 
 
 
 
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 19 of 90  
  
  
 
 
 
 
 
 
 
   
  
 
 
 
  
 
 
[IP_ADDRESS]  Railing System  
   
 
 
 
  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
   
  Study #2014 -04 
Page 20 of 90  
  
 
 
 
 
 
[IP_ADDRESS]  Lock ing Mechanisms   
 
 
 
 
 
 
 
 
 
 
 
 
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 21 of 90  
                 
               
 
 
 
 
 
   
 
  
 
2.4.3 ACCESS SHEATHS  
 
 
[IP_ADDRESS]  Edwards FORMA Tricuspid Transcatheter Guide  Sheath  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
   
   
  
  
 
[IP_ADDRESS]  Edwards FORMA Tricuspid Transcatheter Introducer Sheath  
 
 
 
 
 
 
  
  
 
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
   
  Study #2014 -04 
Page 23 of 90  
 2.4.4 EDWARDS FORMA  TRICUSPID TRANSCATHETER RAILING DELIVERY SYSTEM   
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
                 
 
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 24 of 90  
 2.4.5 EDWARDS FORMA  TRICUSPID TRANSCATHETER RETRIEVAL SYSTEM   
 
 
 
 
   
 
 
 
 
 
 
 
 
3 RISK ANALYSIS  
A risk analysis has been conducted, in accordance with ISO [ZIP_CODE]: 2012  “Application of 
risk management to medical devices”. The risks associated with this investigational device 
have been identified by [CONTACT_688722] (FMEA)/Risk 
Analysis. Risks have been proven minimized through appropriate desig n control, 
confirmed by [CONTACT_688723] , pre-clinical animal testing  and clinical surveillance  presented  
in the Clinical Investigator’s Brochure.  
 
During the conduct  of the clinical study, the existing risk control measures shall be 
reviewed to identify if other hazards have been  introduced.  If any new hazards were 
introduced by [CONTACT_688724], the associated risk(s) shall be re -assessed and 
addressed.   
3.[ADDRESS_934405] cardiac catheterization and the use of anesthesia. Second, 
there are the additional potential risks associated with the use of the FORMA System .  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #[ADDRESS_934406] cardiac catheterization and the 
use of anesthesia may include, but may not be limited to, the following:  
 
• abnormal lab values;  
• acce ss site AV fistula or pseudoaneurysm;  
• allergic reaction to anesthesia or to contrast media;  
• anemia;  
• angina;  
• arrhythmia;  
• bleeding;  
• cardiovascular or vascular injury including perforation, obstruction, or dissection 
of valvular structures that may require intervention, including access sites;  
• conduction system injury (defect) which may require  replacement or 
implantation of a pacemaker  (permanent or temporary) ; 
• death;  
• dyspnea (e.g., orthopnea);  
• electrolyte imbalance;  
• embolization including air, part iculate, calcific material, or thrombus;  
• exercise intolerance or weakness;  
• fever;  
• heart failure;  
• heart murmur;  
• hematoma;  
• hemorrhage requiring transfusion or intervention;  
• leaflet damage;  
• hypertension/hypotension;  
• infection, including septicemia and endocar ditis;  
• inflammation;  
• myocardial infarction;  
• pain or changes at the access site;  
• paralysis;  
• pericardial effusion/cardiac tamponade;  
• permanent disability;  
• pleural effusion;  
• pulmonary edema;  
• renal failure;  
• renal insufficiency;  
• reoperation;  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 26 of 90  
 • restenosis;  
• retroperitoneal bleed;  
• skin burn;  
• syncope;  
• systemic peripheral ischemia/nerve injury;  
• thromboembolic events, stroke, transient ischemic attack, clusters, or 
neurological changes;  
• wound dehiscence, delayed or incomplete healing.  
 
In addition to the risks listed above, additional potential risks associated with the use of 
the FORMA System  may include, but may not be limited to, the following:  
 
• cardiac arrest;  
• cardiac dysrhythmias requiring replacement or implantation of a pacemaker 
(temporary or permanent ); 
• cardiac failure/low cardiac output;  
• cardiogenic shock;  
• chordal damage, rupture;  
• damage to or interference with function of pacemaker or implantable 
cardioverter -defibrillator (ICD); 
• deter ioration of native valve (leaflet tear/tearing, leaflet retraction, leaflet 
thickening, leaflet stenosis, or other);  
• device degeneration;  
• device explants;  
• device migration, malposition or embolization requiring intervention;  
• device thrombosis requiring intervention;  
• emergency cardiac surgery;  
• hemolysis;  
• leakage around device;  
• non-emergent reoperation;  
• nonstructural implant dysfunction;  
• papi[INVESTIGATOR_407744];  
• pneumothorax;  
• pulmonary artery outflow tract obstruction;  
• structural deterioration (wear, fracture, calcification, shaft creep, or other);  
• thromboembolism (permanent or transient pulmonary and/or neurological 
events);  
• transvalvular flow disturbances;  
• valvular regurgit ation;  
• ventricular or atrial wall damage, abrasion, or perforation;  
• worsening of heart failure;  
• worsening of valvular insufficiency.  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #[ADDRESS_934407] the  health, safety or welfare of 
the study patient s. 
3.2 RISK MANAGEMENT  
All effort s will be made to minimize the identified  risks by [CONTACT_688725], team 
members and study sites who meet the following criteria:  
 
• Interventional Cardiologist - must be board certified (or equivalent) , experienced with 
perform ing transcatheter heart valve repair and replacement, and skilled in 
percutaneous coronary  interventions and structural heart interventions . 
• Access  Management  Physician  - must be board certified (or equivalent) , experienced 
with access management (subclavian/axillary vein a ccess) and  right heart  
interventions .  
There will be strong interdepartmental collaboration between interventional cardiology 
and cardiovasculary surgery operators and a designated team of nurses, technicians and 
colleagues from supporting medical discipli nes (e.g., anesthesiologist, heart failure 
specialist , echo -cardiographer, radiologist) .  
 
The procedural location is to be an operating room , catheterization lab  or hybrid 
operating room with fluoroscopic and ec hocardiographic imaging capabilities.  
 
Adverse events will be reviewed by [CONTACT_120776] , Data Safety Monitoring Board and 
Clinical Events Committee as defined in the respective charters. .   
3.3 BENEFITS  
The clinical benefits  of using the FORMA  System  for the treatment of tricuspid  
regurgitation are not known at the present time.  There are no guaranteed benefits from 
participation in this clinical study and being treated with the investigational FORMA  
System . 
 
Tricuspid  valve rep air with the FORMA  System may result in one or more of the following 
benefits for patient s typi[INVESTIGATOR_688701] : 
decrease in tricuspid  regurgitation, acute alleviation of symptoms related to tricuspid  
insufficiency, and/or improved morbidity and mortality.  
Information gained from the conduct of this study may be of benefit to other people with 
the same medical condition in the future as the indication for the system is expanded.  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #[ADDRESS_934408] with the FORMA  System , is designed as a multi -site, prospective, early 
feasibility  study. This study is designed to confirm that the safety and function  observed 
in non -clinical testing is also observed in a limited human population.  
 
The tr eatments currently available for this patient population include palliative medical 
therapy  and high -risk surgical replacement  or repair  of the tricuspid  valve.    Treatment 
with the FORMA  System  may enable patients with tricuspid  regurgitation to undergo 
tricuspid  valve r epair  via a minimally invasive approach.   
4 STUDY OBJECTIVES  
The objectives of this early feasibility  study are to:  
 
• Evaluate the safety and function of the FORMA  System  
• Provide guidance for future clinical study designs utilizing the FORMA  System  
• Provide guidance for future FORMA  System  development efforts  
5 STUDY ENDPOINTS  
5.1 FEASIBILITY ENDPOINTS   
5.1.1 SAFETY  ENDPOINT  
Composite of major adverse events (MAE) defined as cardiovascular mortality, 
myocardial infarction, new need for renal replacement therapy, severe bleeding and re -
intervention for study device related complications at 30 days.  
 
5.1.2 PERFORMANCE ENDPOINT  
[IP_ADDRESS]  Device Success   
Device is deployed as intended and the del ivery system is successfully retrieved as 
intended at the time of the patient’s exit from the cardiac catheterization laboratory.  
[IP_ADDRESS]  Procedural Success  
Device success with evidence of TR reduction as evidenced by a relative reduction in EROA 
of ≥ 30% from baseline to discharge and without the need for a surgical or percutaneous 
intervention prior to hospi[INVESTIGATOR_2345].  
[IP_ADDRESS]  Clinical  Success  
Procedural success without MAEs at 30 days.   (MAEs: cardiovascular mortality, myocardial 
infarction, new need for renal replacement therapy, severe bleeding and re -intervention 
for study device related complications)  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
   
  Study #2014 -04 
Page 29 of 90  
 6 STUDY  DESIGN  
This is a multi -site, pros pective, early feasibility  study designed to evaluate the safety and 
function of the FORMA  System . 
 
A total of sixty  patient s will be enrolled in the study.   All enrolled study patient s will be 
assessed for clinical follow -up at the following intervals:  [ADDRESS_934409] m eet all of the following inclusion criteria and none of the 
exclusion criteria:  
7.2 INCLUSION CRITERIA  
The Investigator has the responsibility of screening potential patient s to determine if the 
patients meet all the inclusion criteria.  The following are req uirements for entry into the 
study:  
 
1. Signed and dated IRB approved study consent form prior to  study related 
procedures  
2. ≥ eighteen (18) and ≤ eighty five (85) years old   
3. Symptomatic severe (Stage D)  functional, tricuspid regurgitation (per applicable 
guidelines) requiring transcatheter tricuspid valve repair as assessed by [CONTACT_407783]  (a minimum of one cardiologist and one cardiac surgeon)    
4. Signs or symptoms of persistent right heart failur e despi[INVESTIGATOR_247482]  
5. Willing to attend study follow -up assessments for up to 3 years  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #[ADDRESS_934410] exclude patient s if any of the exclusion criteria are 
present. The following are the criteria for exclusion from participating in the clinical study : 
 
1. Tricuspid valve/right heart anatomy not suitable for the study device:  
a. Native tricuspid annulus area  < 2.63 cm2 (12 mm device)  or < 3.27cm2 (15 mm 
device ) as measured by [CONTACT_688726]  
b. Sub-valvular structures/anatomy that would preclude proper anchor or 
Spacer  placement, positioning and retrieval  
c. Access pathway vessel diameter < 7.1 mm ( Introducer Sheath ) or < 8.0 mm 
(Guide Sheath)  
2. Moderate or greater tricuspid valve stenosis  
3. EROA ≥ 1.0 cm2 by [CONTACT_976][INVESTIGATOR_688695] ≥ 2.0 cm2 by 3D measurement  
4. Severe RV dysfunction as evidenced by [CONTACT_472571] < [ADDRESS_934411] 180 days, or that precludes 
proper placement of the device, or may interfere with the device, or presence of 
two or more RV leads  
6. RV lead with pacemaker dependency  
7. Untreated clinically significant coronary artery disease requiring immediate 
revascularization  
8. Any therap eutic invasive cardiac procedure performed within 30 days of the 
scheduled implant procedure  
9. Patient on chronic dialysis  
10. Patients with renal insufficiency  (eGFR < 30 mL/min/1.73 m2)  
11. Patients with chronic anemia (Hb <9 g/L)  
12. Patients with  thrombocytopenia (platelet count <100,000/mm3) 
13. Patients with  significant pericardial effusion  
14. Significant stenosis of the left subclavian vein that may preclude safe 
introduction of the delivery catheter  
15. Myocardial infarction or unstable angina  within 30 d ays of scheduled implant 
procedure  
16. Hemodynamic instability or on IV inotropes within 30 days of scheduled implant 
procedure  
17. Patient requiring surgery under general anesthesia for any reason within 30 days 
of scheduled implant procedure  
18. Severe left ventricular dysfunction with ejection fraction < 30% within 90 days  of 
scheduled implant procedure  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 31 of 90  
 19. Patients with systolic pulmonary artery pressure > 60 mmHg  via transthoracic 
echocardiography or right heart catheterization within 90 days  of scheduled 
implant procedure  
20. Patients with uncontrolled hypertension defined as SBP ≥ 180 mmHg or DBP≥ 
110 mmHg  
21. Aortic, and/or pulmonic valve stenosis and/or regurgitation graded as moderate 
or greater  
22. Mitral  stenosis or regurgitation graded as severe  
23. Active endocarditis or infection within [ADDRESS_934412] (6MWT) < 150 meters and > 400 meters within 90 days of 
scheduled implant procedure  
26. Significant frailty (i.e. Katz Index of Independence in Activities of Daily Living (ADL) 
≤ 2) within 90 days of scheduled implant procedure  
27. Chronic liver disease with a MELD score of 12 or grea ter 
28. Recurrent (>2 per 12 months) hospi[INVESTIGATOR_688702]  
29. Non -cardiac disease limiting life expectancy to be less than 12 months at baseline 
evaluation  
30. Documented history of bleeding diathesis, coagulopathy or gastrointestinal 
bleeding within 90 days  of scheduled implant procedure  
31. Evidence of left or right sided intracardiac mass, thrombus, or vegetation  
32. Prior venous stent placed within the access route (e.g ., sub -clavian vein) that could 
negatively react with device  
33. Previous implantation of a bioprosthetic or mechanical tricuspid valve or a leaflet 
repair device  
34. Known hypersensitivity to cobalt chromium, nitinol or titanium  
35. Known hypersensitivity to anticoagulation therapy or contrast agent, which 
cannot be adequately medicated  
36. Patient is a current intravenous drug user  
37. Female of child -bearing potential is pregna nt or lactating  
38. Patient is currently participating in another drug or device clinical study  
39. Patient requires emergent/emergency treatment for tricuspid insufficiency  
40. Patient is under guardianship  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #[ADDRESS_934413] ( IRB), and/or 
FDA (as required).  A sample Informed Consent Form is provided in Appendix A – Sample  
Informed Consent Form .   
Once the patient’s physician has determined the patient’s eligibility for the study, the 
background of the proposed study, and the benefits and risks of the procedures and study 
should be explained to the patient.  The patient ( or the patient’s legal representative ) 
must sign the institution’s approved Informed Consent Form prior to participation.  
Failure to provide informed consent renders the patient ineligible for the study.  
The consent form will be written in the native language of the patient and administered 
only by [CONTACT_688727].  The Principal Investigator [INVESTIGATOR_688703], risks and benefits 
of the study were explained to the patient and that their signature [CONTACT_407826].  
The Investigator will retain the original consent form, a copy will be filed  in the patient’s 
medical record, and a copy of the Informed Consent Form will be provided to the patient.  
Informed consent MUST be obtained prior to any study related procedures .   Signed 
informed consent form s must be retained by [CONTACT_688728] -site 
monitoring visit s.  
8.2 PATIENT  ENROLLMENT  
A Screening/Enrollment Log , provided by [CONTACT_1034], will be maintained at the study site 
to document the screening and enrollment of all patient s assessed for study participation.  
The screening of patient s qualifying for this study should be carried out in a sequential, 
prospective manner, such that all patients are offered the possibility of participating in 
the study , and are therefore evaluate d according to the selection criteria defined in this 
protocol.  Patient s who are consented to participate in the study but do not fulfill 
enrollment criteria, will be considered “screen failures” and will not count towards the 
overall enrollment cap.  T he reason for “screen failure” will be recorded on the screen 
failure log.  Reasons for screen failure may include but are not limited to:  
• Qualifying patient is not offered an opportunity to participate by [CONTACT_10670]  
• Qualifying patient  refuses to particip ate 
• Investigator opts for alternative therapy for qualifying patient    
• Potential patient  fails the screening criteria   
All patient s assessed for study participation that have signed the informed consent form 
will be entered on the screening log.  These patient s will be assigned a sequential patient  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 33 of 90  
 ID number by [CONTACT_12925] .  The patient  ID number together with the patient  initials 
shall be used to identify the patient  on all study -related documents.  
Patient will be considered  “provisionally  enrolled” when they have signed the informed 
consent form agreeing to participate in the study  and have been deemed eligible for study 
participation by [CONTACT_407813] (S ections 7.2 -7.3).  A patient will be considered 
“enrolled” at the time of skin incision to introduce  the FORMA System  into the body . 
8.[ADDRESS_934414] been determined to 
be eligible study candidates and agreed to participate in the study.  
2. Medical History  (includes 12  month s prior hospi[INVESTIGATOR_688704] ( ED) visits , paracentesis ), Clinical Evaluation (includes vital signs, 
concomitant medical treatments , edema grading, weight and height) and NYHA 
classification  
3. Administration of Health Status Questionnaires (e.g., SF -12, KCCQ ) 
4. Administration of Six Minute Wa lk Tes t  (6MWT)  
5. Administration of Katz Index of Independence in Activities of Daily Living (ADL)  
6. Calculation of MELD  score for liver disease prognosis  
7. Clinical Laboratory Tests  
a. The following lab tests sha ll be done within 30 days of the scheduled 
implant procedure:  
i. Troponins and cardiac enzymes (CK -MB) - MI within 30 days of the 
scheduled implant procedure is an exclusion from study 
participation  
b. The following lab tests shall be done ≤ 2 weeks before  implant  procedure : 
i. NT-pro Brain Natriuretic Peptide ( BNP ), and if not available BNP  
ii. CBC  and platelet count  
iii. Complete metabolic panel  
iv. Liver panel  including gamma -glutamyl transferase  (GGT)   
v. Serum Creatinine  and eGFR  
c. The follow ing lab tests shall be done ≤ 48  hours before the implant 
procedure:  
i. HCG for women who are not sterile or post -menopausal - positive 
result is an exclusion from study participation.  
ii. INR and PTT/aPTT   
8. Standard 12 -lead Electrocardiogram ( ECG)  
9. Comprehensive Transthoracic Echocardiogram (TTE), (within 90 days of scheduled 
implant procedure)  including but not limited to, annulus size, ventricular size, 
regurgitant assessment , jet location , mean pulmonary artery pressure (PAP),  LVEF , 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 34 of 90  
 and pulmonary  vascular resistance (PVR)   [10].  Analysis will be conducted by [CONTACT_688729]5. 
10. Transesoph ageal Echocardiogram  (TEE), (within 90 days of scheduled implant 
procedure)  including but not limited to  transgastric views . 
11. All candidates must have pre -implant procedure imaging , (within 90 days of 
scheduled implant procedure), that captures the anatomy of the  subclavian and 
axillary veins, superior vena cava , tricuspid valve a nd sub -valvular 
structures/anatomy , right atrium and right ventricle.  Analysis will be conducted by 
[CONTACT_688730] .   
If a pre -existing Computed Tomography (CT) within [ADDRESS_934415] is not clinically indicated (e.g. no recent cardiac events that would 
alter the anatomy  or no cardiac procedures performed since prior CT) , the baseline 
CT can be waived and is not required to be repeated.  
12. Invasive Hemodynamic Monitoring/Right Heart Catheterization (within 90 days of 
scheduled implant procedure) that should include, but is n ot limited to, right atrial 
pressure (RAP) , PAP, right ventricle pressure (RVP), cardiac output  (CO), and PVR 
measurements.[ADDRESS_934416] a venogram (subclavian and axillary 
veins) as part of pre -implant procedure imaging  (within 90 days of scheduled 
implant procedure) , if venous patency can not be determined by [CONTACT_094] -procedure CT . 
14. Candidates with pacemaker leads must have interrogation of their device within [ADDRESS_934417] interrogation within 180 days.  
15. Coronary angiogram within  1 year of the scheduled implant procedure  
 
Baseline data to be collected will include but is not limited to the information listed in the 
following table:  
 
5 If candidate had new cardiac procedure since baseli ne TTE and TEE that were submitted for screening, 
the TTE and TEE should be repeated and resubmitted.  
6 If the screening echo confirms the PAP meets the study criteria, the right heart catheterization/ 
hemodynamic assessment at the baseline evaluation may be waived.   

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 35 of 90  
 Table 6 - Baseline Evaluation  
 
General Information  Clinical Information  Laboratory Measurements  
• Inclusion/exclusion  
evaluation  
• Informed consent  
• Age 
• Gender  
• Height  
• Weight  
 • Local Heart Team 
determination  
• Medical history  (e.g., 
EuroSCORE , STS Score ) 
/prior cardiovascular 
interventions / surgeries  / 
12-month prior 
hospi[INVESTIGATOR_688705]  
• Vital signs (Blood pressure, 
heart rate) 
• Edema grading  
• Concomitant Medication s 
and doses  
• NYHA classification  
• Echocardiographic  
measurements  (TTE & TEE),  
tricuspid regurgitation & 
heart function within 90 
days of scheduled implant 
procedure  
• Computed Tomography 
(CT) 
• Coronary angiogram  within 
1 year  
• Venogram ( in patients with 
cardiac  lead s) if required  
• Interrogation  of pacemaker 
leads  within 180 days  
• Invasive Hemodynamic 
Monitoring/Right Heart 
Catheterization including 
pressure measurements   
• ECG results  
• Six minute walk test  
• Katz Index (ADL)  test 
• MELD  score  
• KCCQ & SF -12 
questionnaires  Within 30 days  of procedure : 
• Date of blood draw  
• Troponin1 and CK-MB1 
 
Within ≤ 2 weeks of 
procedure : 
• Date of blood draw  
• NT-pro BNP  (preferred) or 
BNP  
• Serum Creatinine & eGFR  
• WBC  
• RBC 
• Hematocrit  
• Hemoglobin  
• Platelets  
• ALT/SGPT  
• AST/SGOT  
• Bilirubin   
• LDH 
• GGT  
• ALP 
• Albumin  
• Sodium & potassium  
• Urea  
Within ≤ 48 hours  of 
procedure:  
• INR  & PTT/ aPTT  
• HCG , if applicable3 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 36 of 90  
 1. MI within 30 days of the scheduled implant procedure is an exclusion from study participation  
2. A positive result is an exclusion from study participation  
8.4 ANTIPLATELET / ANTICOAGULATION THERAPY   
 
Recommendations for antiplatelet/anticoagulation therapy are detailed below  and in 
Table 7.  Alternative anticoagulation/antiplatelet regimens may be considered according 
to the needs of individual patients or a hospi[INVESTIGATOR_307]’s standard practice; these will not 
constitute a protocol deviation.  For study patients on an existing dual antiplatelet therapy 
or with known hypersensitivity to the required medications, the investigator will 
determine the  antiplatelet/anticoagu lation therapy.  
 
Patients on anticoagulation (e.g. Warfarin  or Api[INVESTIGATOR_3822]) will discontinue use prior to 
implant procedure.  Patient s not on anticoagulation  prior to the procedure should  receive 
Aspi[INVESTIGATOR_248] (at least 75 – 100 mg daily) and Plavix (300 mg or per investigator’s preference ) 
prior to implant procedure.    
 
Heparin will be administered at procedure start , before introduction of any catheter into 
the vasculature .  During the procedure, ACT will be monitored and recorded on source 
documentation.  Hep arin will be administered during the procedure as needed to 
maintain the patient ’s ACT at ≥  [ADDRESS_934418]  level is 
appropriate (e.g., reaches < 150 sec ) after implantation of the study devices . 
 
Post procedure, patient s on Aspi[INVESTIGATOR_688706] -platelet 
therapy through the [ADDRESS_934419] the 6 -month 
follow -up visit will be determined at the Investigator’s discretion . 
 
Patients on anticoagulation (e.g. Warfarin  or Api[INVESTIGATOR_3822]) will continue with their prescribed 
anticoagulation medications  post implant procedure through the 6 -month follow -up visit . 
 See Table 7. 
 
Table 7 – Summary of Recommended Concomitant Medical Therapy  
     *Anticoagulant: e.g., Warfarin or Api[INVESTIGATOR_3822]  
 
 
 
.   Visit  Patients on anticoagulant* prior 
to implant procedure  Patients Not on anticoagulant* 
prior to implant procedure  
Pre Procedure  Discontinue anticoagulant  Start Aspi[INVESTIGATOR_688707]-Procedure  IV Heparin  IV Heparin  
Post -Procedure 
through Month 6  Resume anticoagulant  Continue Aspi[INVESTIGATOR_688708] K   
  Study #2014 -04 
Page 37 of 90  
 8.5 DEVICE PREPARATION  
A description of device preparation and use is provided in the IFU s, (See Report of 
Priors/ Clinical Investigator’s Brochure). Investigators must be familiar with the 
information described in the IFU prior to use of the  FORMA  System .  
 
An Edwards Representative that has been trained on the preparation of the  FORMA  
System  will be in attendance at all implant procedures.  
8.6 IMPLANT PROCEDURE   
The implant procedure shall be performed under general anesthesia with hemodynamic 
monitoring in  an operating room , catheterization lab or hybrid operating room  with 
fluoroscopic and echo cardio graphic imaging capabilities.  The use of cardiopulmonary 
by[CONTACT_688731] . 
 
The following study procedures  will occur during the implant procedure:  
 
1. Safety Evaluation  
2. Transesophageal Echocardiogram   
3. Ventriculogram Imaging  
4. Invasive Hemodynamic Monitoring /Right Heart Catheterization including right 
atrial pressure measurements pre and post implant  
5. Heparin administration to achi eve (and maintain)  an ACT of ≥ 250 sec during the 
implant procedure  
 
Patient s will be monitored in the operati ng room as needed  with special attention to 
hemodynamic condition and cardiac rhythm.  Subsequent monitoring of patient s will be 
continued in the recovery room or ICU.  
 
The date of the implant procedure will be considered as Day 0 for the purpose of 
determ ining specified time intervals for the follow up visit for the implanted and non -
implanted cohorts.  
 
Procedure  data to be collected will include but is not limited to the information  listed in 
the following table : 
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 38 of 90  
 Table 8 – Procedure Information  
 
General Information  Clinical Information  Laboratory Measurements  
• Hospi[INVESTIGATOR_55110]  
• Patient  identification 
number  
• Names of 
Interventional 
Cardiologist & Access 
Management Physician  
• Procedure date  
• Access site  
• Timing of implant 
procedures  
• FORMA  System 
identification & 
disposition  • Fluoroscopy duration & 
contrast volume  
• Heparin administration 
& ACT levels  
• TEE measurements , 
tricuspid regurgitation & 
heart function  
• Ventriculogram  Imaging  
• Invasive Hemodynamic 
Monitoring /Right Heart 
Catheterization and 
pressure measurements  
performed  
• Adverse events  
• Device malfunction  Within [ADDRESS_934420] 
implant:  
• Troponin1 and  
CK-MB1 
• NT-pro BNP  (preferred ) 
or BNP  
• WBC  
• RBC 
• Hematocrit  
• Hemoglobin  
• Platelets  
• ALT/SGPT  
• AST/SGOT  
• Bilirubin  
• LDH 
• GGT  
• ALP 
• Albumin  
• Sodium & potassium  
• Urea  
• Serum creatinine & 
eGFR  
• PTT/aPTT & INR 
 
1. If an elevation was noted post implant (within 48 hours), tests must be repeated three times or 
until not clinically significant  
 
8.6.[ADDRESS_934421] media is required for these patients. Accurate 
measurement of the dye used during the implant procedure shall be  captured in the 
appropriate case report form.  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #[ADDRESS_934422] implant procedure : 
 
1. Clinical Evaluation  
2. Safety Ev aluation  
3. Clinical Laboratory Tests  
a. NT-pro BNP  (preferred) or  BNP  
b. CBC and platelet count  
c. Complete metabolic panel  
d. Liver panel  
e. PTT/aPTT  and INR  
f. Serum creatinine  and eGFR  
g. Troponins and cardiac enzymes (CK -MB)  
4. Standard 12-lead ECG  
8.6.4 DISCHARGE  
The following procedures w ill be performed prior to discharge from the hospi[INVESTIGATOR_307] /unit :  
 
1. Clinical Evaluation  and Concomitant Medications   
2. Safety Evaluation  
3. Clinical Laboratory Tests  
a. NT-pro BNP (preferred) or  BNP  
b. CBC  and platelet count  
c. Complete metabolic panel  
d. Liver panel  
e. INR and  PTT/aPTT   
f. Serum creatinine  and eGFR   
g. Troponins and cardiac enzymes (CK -MB) , only required if an elevation was 
noted post implant (within 4 8 hours)  
4. Standard 12 -lead ECG  
5. Comprehensive Transthoracic Echocardiogram,  including but not limited to,  
annulus size, ventricular size,  regurgitant assessment  and jet location  
Discharge  data to be collected will include but is not limited to the information  listed in 
the following table : 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 40 of 90  
 Table 9 – Discharge Information  
 
General Information  Clinical Information  Laboratory Measurements  
• Discharge date  & 
location  
discharged to 
(e.g., home)  
• Weight  
 • Clinical e valuation 
(mobility, edema, ascites, 
access site)  
• Vital signs (Blood Pressure, 
Heart Rate)  
• TTE measurements, 
tricuspid regurgitation & 
heart function   
• ECG results  
• Concomitant medications  
and doses  
• Adverse events  
 
 • Date of blood draw  
• Troponin  and CK-MB, if 
applicable  
• NT-pro BNP  (preffered) or 
BNP  
• WBC  
• RBC 
• Hematocrit  
• Hemoglobin  
• Platelets  
• ALT/SGPT  
• AST/SGOT  
• Bilirubin  
• LDH 
• GGT  
• ALP 
• Albumin  
• Sodium & potassium  
• Urea  
• Serum creatinine & eGFR  
• INR & PTT/ aPTT  
 
8.[ADDRESS_934423] 
implant procedure intervals as illustrated in  Table 11. The following procedures will be 
conducted during follow up visits:  
 
1. Clinical Evaluation  Hospi[INVESTIGATOR_4355]/ or Clinic Visits  and Paracentesis , 
Concomitant Medications  and doses , Edema Grading  and NYHA classification  
2. Administration of Health Status Questionnaires (e.g., SF -12, KCCQ ) 
3. Administration of Si x Minute Walk Test  
4. Safety Evaluation   
5. Clinical Laboratory Tests :  
a. NT-pro BNP  (preferred) or BNP  
b. CBC  and platelet count  
c. Complete metabolic panel  
d. Liver panel  

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 41 of 90  
 e. INR and PTT/aPTT   
f. Serum creatinine  and eGFR  
6. Calculation of MELD  score for liver status  
7. Standard 12 -lead ECG  
8. Comprehensive Transthoracic Echocardiogram, including but not limited to,  
annulus size, ventricular size,  regurgitant  assessment  and jet location  
Follow -up data to be collected will include but is not limited to the information  listed in 
the following table : 
 
Table 10 – Follow -Up Visit Information  
 
General Information  Clinical Information7 Laboratory Measurements  
• Visit date  
• Height  
• Weight  
 • Clinical evaluation 
(mobility, edema  grading , 
ascites, access site)  
• Vital signs (Blood Pressure, 
Heart Rate)  
• Hospi[INVESTIGATOR_602] &/or clinic 
visits & paracentesis  
• NYHA classification  
• TTE measurements, 
tricuspid regurgitation & 
heart function  
• ECG results  
• Six minute walk test (pre & 
post walk data & results)  
• KCCQ & SF -12 
questionnaires  
• MELD  score  
• Concomitant Medication s 
and doses  
• Adverse events  • Date of blood draw  
• NT-pro BNP  (preferred) or 
BNP  
• WBC  
• RBC 
• Hematocrit  
• Hemoglobin  
• Platelets  
• ALT/SGPT  
• AST/SGOT  
• Bilirubin  
• LDH 
• GGT  
• ALP 
• Albumin  
• Sodium & potassium  
• Urea  
• Serum creatinine and eGFR  
• INR  & PTT/ aPTT  
 
8.7.[ADDRESS_934424] implant procedure intervals as illustrated 
in Table 11 below:  
 
7 To be documented in the medical records or chart.  
 

Edwards FORMA Tricuspid Transcatheter Repair System  Early Feasibility  Study   
 
Version K   
  Study #2014 -04 
Page 42 of 90  
  
 
Table 11 – Follow -up Visit Windows  
 
Scheduled Follow -up Interval  Follow -up Window  
1 month (30 days)  ± 7 days  
6 months (183 days)  ± 30 days  
Annual ly  (365 days) up to  3 years  ± [ADDRESS_934425] the study procedure attempted (at least skin incision to introduce the FORMA 
system)  are considered enrolled in the study .  
 
Patients who enter the procedure room but who do not have the study procedure  
attempted  (at least skin incision  to introduce the FORMA system ) will be classified as 
“non -implanted” and will be followed [ADDRESS_934426] udy follow up visit procedures.  
 
 

Edwards FORMA Tricuspid Transcatheter  System  Early Feasibility  Study   
   
 
Version K  
 Study #2014 -04  
Page 43 of 90 
 Table 12 – Summary of Required Study Procedure s 
 
[ADDRESS_934427] be scheduled within 90 days of baseline TTE and TEE  and pre-implant procedure imaging  (CT and/or angiographic imaging ).  If a pre-existing CT within 180 days of the 
scheduled implant captures all the required anatomy for necessary measurements & the anatomy has not changed, the baseline CT can be waived & is not  required to be repeated . 
2 Discharge from hospi[INVESTIGATOR_307] /unit  post implant procedure  
3 HCG for women wh o are not sterile or post -menopausal  
[ADDRESS_934428] implant (within 4 8 hrs) 
5 If the screening echo confirms the PAP meets the study criteria, the right heart catheterization/ hemodynamic assessment at t he baseline evaluation may be waived.  STUDY PROCEDURES  BASELINE  IMPLANT  
PROCEDURE1 
(Day 0)  DAY 1 
(24-48 hrs)  DISCHARGE2  1 MONTH  
 (30 ± 7 days )  6 MONTHS  
(183 ± 30 days)  ANNUAL   
 (for 3 yrs)  
(365 ± 45 days)  
Informed Consent  X       
Medical History  X       
Clinical Evaluation /Concomitant Medications  X  X X X X X 
Hospi[INVESTIGATOR_602] &/or clinic visits  &  paracentesis  X    X X X 
NYHA Class Assessment  X    X X X 
Health Status Questionnaires  X    X X X 
Six Minute Walk Test  X    X X X 
Katz Index (ADL) test   X       
MELD  score  X    X X X 
Safety Evaluation   X X X X X X 
Pacemaker interrogation (pacemaker patients)  X       
Coronary angiogram  (within 1 year of procedure)   X       
Complete Metabolic Panel  and  Liver Panel   X  X X X X X 
NT-pro BNP / BNP and  CBC  and Platelet Count   X  X X X X X 
INR & PTT/aPTT   X  X X X X X 
HCG  X3       
Serum creatinine  and eGFR  X  X X X X X 
Troponins and CK-MB X  X X4    
ECG X  X X X X X 
Transesophageal Echocardiogram  X X      
Transthoracic Echocardiogram  X   X X X X 
Pre-Implant Procedure Imaging  
(CT/ Angiographic Imaging  & venogram for cardiac  
lead patients , if required ) X     
  
Ventriculogram Imaging   X      
Invasive Hemodynamic Monitoring  X5 X      

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04  
Page 44 of 90 
  
 8.8 MISSED PATIENT  VISITS  
The Investigator shall inform study patient s of the importance of returning for scheduled 
follow -up visits and report ing any address or telephone number changes .  The 
Investigator shall make every attempt to follow the  study  patient s. 
 
The Investigator sh all keep a separate log of the patient s’ names and current contact 
[CONTACT_688732][INVESTIGATOR_688709] s for future 
follow -up.  If a patient  cannot be reached for a follow -up assessment, the Investigator will 
document  the missed visit and effort made to contact [CONTACT_90323] , the patient ’s primary 
health care provider, and/or hospi[INVESTIGATOR_688710].   
Patient s who miss a visit will not be considered withdrawn, and an effort to contact [CONTACT_688733] -up visit interval will be made by [CONTACT_737].   
8.9 WITHDRAWAL CRITERIA AND PROCEDURES  
The Investigator will make every attempt to follow the patient s at each of the required 
assessment periods. The reason for the withdrawal will be documented on the 
appropriate case report forms and in the medical records for each patient  who has 
withdrawn.  
 
Patient s may be withdrawn from the study for any of the fol lowing reasons:  
 
• Patient  Withdrawal  
The patient  may voluntarily withdraw from the clinical study at any time, without 
penalty or loss of benefits to which they are otherwise entitled .  
 
• Physician Withdrawal  
The Principal Investigator [INVESTIGATOR_357401] a patient  if s/he  feels it is in 
the best interest of the patient  to do so.  
 
•    Lost to Follow -up  
If a patient  cannot be reached for a follow -up visit, the Investigator will document the 
contact [CONTACT_688734]/or eff ort to obtain hospi[INVESTIGATOR_1097] i n the 
appropriate electronic case report form. If the patient  cannot be reached in any way, 
or misses a visit, the patient  will be considered “unable to contact” for that time 
interval. After three (3) documented unsuccessful attempts to make contact [CONTACT_688735], a certified letter will be sent to the patient ’s residence. If there is no 
response after the certified letter is sent, the patient  will be considered “lost to follow -
up.”  
 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04  
Page 45 of 90 
  
 In all cases of withdrawal (as described above), withdrawn patient s will not undergo 
further study follow -up procedures after the time of study exit. A study patient  that has 
been withdrawn from the study will not be replaced.  
8.10 PATIENT  STUDY COMPLETION   
Study patient s complete and exit the study when no additional follow -up visits,  
procedures, or data collection are required. Patients will then continue to be followed by 
[CONTACT_688736] .   
 
A patient  will also be exited from the study in the following instances:  
 
• Patient  signs informed consent form, is deemed eligible but does not undergo the 
study procedure   
• Patient  has study procedure attempted  (at least skin incision  to introduce the FORMA 
System ) and does not have the  investigational device  implanted  (will exit study at the 
1 month  follow up visit)  
• If the study device is explanted, the patient will be followed for 30 days after the 
explant procedure  for safety evaluations only , and will be exited from the study at 
that point. If one or more ongoing adverse event(s) related to the explant procedure 
is unresolved 30 days after the explant, the patient will remain in the study until the 
adverse event(s) have been resolved, or [ADDRESS_934429]  
• Patient  is lost -to-follow -up  
• Patient  withdraws participation from the study or is withdrawn from the study  
• Patient  expi[INVESTIGATOR_1516]  
9 TRAINING  
9.1 INVESTIGATORS DEVICE  TRAINING  
 
 
 
   
 
 
 
9.2 TRAINING  OF INVESTIGATIONAL  SITE PERSONNEL  
 
 
 
 
cific 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #[ADDRESS_934430], 
the study site has obtained applicable regulatory (e.g., IRB, FDA) approvals, and a patient  
eligible for implant has been identified.   
 
Devices will be provided to the study site as needed for scheduled implant procedures.  
All investigational devices used in this study for investigational purposes will be labeled 
“Caution: Investigational Devi ce, Limited by [CONTACT_4496] ([LOCATION_003]) law to investigational use ”.   
10.[ADDRESS_934431] inventory and shipment records. Devices may be hand 
carried to participating study sites by [CONTACT_688737] (packing lists, transfer of 
inves tigational product form, etc). The Investigator(s) or designee will take inventory of 
the product and complete the delivery documentation with receipt date and signature. 
Both the study site and the Study Sponsor will retain copi[INVESTIGATOR_91678]. The 
Investigator will maintain a Device Accountability Log (as provided by [CONTACT_1034]) of all 
investigational devices documenting their receipt, disposition and return during this 
clinical study. The log will be kept with the documents for the clinical study and will be 
available for review during Study Sponsor monitoring visits.  
 
Upon Sponsor request or when enrollment has ended, FORMA  System  components must 
be returned to Edwards Lifesciences and the date of return must be recorded on the log.  
10.3 DEVICE STORAGE  
The device  inventory will be stored in a  locked , controlled, cool  and dry area  as described 
in the IFU  and/or presented on the device labeling .  This secured area will be only 
accessible to the Investigators or approved designee.  Only investigators trained and 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04  
Page 47 of 90 
  
 identified in the Delegation of Authority form on file at Edwards Lifesciences may use the 
investigational device s. 
10.4 DEVICE RETURN  
The Investigator will be notified in writing upon terminat ion of the clinical study. All 
unused devices in original package and/or those in opened packages as well as those 
removed from the original package will be returned upon receipt of this notice.   The 
Investigator will receive instructions from the Study Sp onsor on the return process.  The 
Investigator’s copy of the Device Accountability log must document any unused devices 
that have been returned.  
 
Used devices may be handled and disposed of in the same manner as hospi[INVESTIGATOR_688711]-hazardous materials i n accordance with local regulations. There are no special risks 
related to the disposal of these devices. All returns and dispositions of devices will be 
captured on the Device Accountability Log Procedure needed.  
11 DATA COLLECTION AND REPORTING  
11.1 DATA COLLECTION  METHODS  
The Study Sponsor will provide the study site with the clinical protocol, electronic case 
report forms, sample informed consent form, and all other necessary study -related 
documents.  Study Sponsor’s Clinical Affairs Department, or design ee, will conduct all 
aspects of data quality control and assurance of the study site including but not limited 
to, data reviewing, data monitoring, and form collection.  
11.[ADDRESS_934432] be 
fully completed for each patient, and signed electr onically by [CONTACT_1755]/or 
designee. If for any reason the eCRFs are unavailable, or access to the electronic database 
is limited, paper CRF forms must be completed and submitted to study manager. The 
eCRFs should be completed at the first earlies t opportunity.  
 
The investigator, or an individual designated by [CONTACT_12552]/her, is responsible for recording all 
data from the study  onto the eCRFs on a dedicated website.   All data entered is subjected 
to data type verification and range checking.   The operator  is notified of errors that may 
occur, and depending on the data verification sub -routines, the operator might need to 
resolve that error before moving to the next entry field.   The investigator is required to 
provide an electronic signature [CONTACT_688751]/she has 
reviewed the recorded data.  
 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #[ADDRESS_934433] to be addressed by [CONTACT_977].  
11.3 SOURCE  DOCUMENTATION  REQUIREMENTS  
The Clinical Research Coordinator (CRC) designated by [CONTACT_737], and documented 
on the Del egation of Au thority log, will perform primary data collection drawn from 
source documentation review ( patient ’s medical record) . All data that is enter ed in the 
eCRFs must have source documentation available in the patient  medical records.  Protocol 
deviation information can be recorded directly on the protocol deviation eCRF.  Data to 
be collected for the study purposes must not be entered  directly onto eCRFs . The data 
must be recorded from original source documents and available for review by [CONTACT_8760]. Regulations require that Investigators maintain information in the study 
patient ’s medical records that corroborate data collected on the eCRFs. The source 
documentation may consist of but is not limited to: operative or procedure rep orts, 
progress notes, discharge summaries, laboratory reports, radiographic reports, 
medication logs, and worksheets. Source Documents may be in electronic form and/or 
hard (paper) copi[INVESTIGATOR_014].  
11.[ADDRESS_934434] results may be kept on file in the Investigator’s 
patient  study  files.  Access to e CRFs and copi[INVESTIGATOR_110161].  
 
All clinical sites will be audited periodically by a study monitor employed by [CONTACT_688738], accuracy of eCRFs, and c ompliance to applicable 
regulations.   Evident patterns of non -compliance with respect to these standards will be 
cause for the site to be put on probation for a period of one month.   If corrective actions 
are not subsequently undertaken, the clinical site will be asked to withdraw.  

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #[ADDRESS_934435] standards of availability and security:  
 
• Hosting facility is a multi -level protected environment.  
• Access is severely restricted with high -end user recognition technology.  
• Multi -points backup of critical data is standard.  
• Firewalls and other undisclosed technologies provide strong data security.  
• Availability all year -round 24 hours a day.  
 
Passwords will be issued to appropriate data management personnel to ensure 
confidentiality and protection of the data by [CONTACT_407799].  
12 REPORTABLE EVENTS / EFFECTS  
12.1 DEFINITIONS  
12.1.1  ADVERSE EVENT  
An AE is defined in ISO [ZIP_CODE]:[ADDRESS_934436] clinical signs (including abnormal laboratory finding) in 
subjects, users or other persons, whether or not related to the investigational medical 
device . 
  
Note:  a nticipated adverse events are adverse events that have been identified as possible 
adverse events related to the investigational medical device or the study procedure.   The 
anticipated events of this clinical study are outlined in Section 3.1, Potential Risks  
12.1.[ADDRESS_934437]  (ADE) is defined in ISO [ZIP_CODE]:2011 as any adverse event related 
to the use of an investigational medical device. This  definition includes:  
- Adverse event resulting from insufficient or inadequate instructions for use, 
deployment, implantation, installation, or operation, or any malfunction of the 
investigational medical device.   
- Any event resulting from use error or from intentional misuse of the 
investigational medical device.  
12.1.3  SERIOUS ADVERSE EVENT  
A serious adverse event (SAE) is defined in ISO [ZIP_CODE]:2011 as an adverse event that:  
1. led to death  
2. led to serious deterioration in the health of the subject that either resulte d in :  
a. a life -threatening illness or injury, or  

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #[ADDRESS_934438] (not 
anticipated in this study as pregnant women are excluded from the study).  
12.1.[ADDRESS_934439] (SADE) is defined in ISO [ZIP_CODE]:[ADDRESS_934440] ([LOCATION_003]DE) is defined in ISO [ZIP_CODE]:[ADDRESS_934441] which by [CONTACT_5942], incidence, severity or outcome has not been 
identified in the risk analysis section of the study protocol.  
12.1.6  DEVICE DEFICIENCY AND MALFUNCTION  
Device deficiency is defined in ISO [ZIP_CODE]:2011 as an inadequacy of a medical device with 
respects to its identity, quality, durability, reliability, safety or performance.  
 
Device deficiencies include malfunctions, use errors and inadequate labeling.  
 
Device malfunction is defined in ISO [ZIP_CODE]:[ADDRESS_934442].  
 
Device migration is defined in ISO 5840 -3 as detectable movement or displacement of the 
device from its original position within the implant site, without embolization.  
 
Structural component failure is defined as degradation of structural integ rity of the 
support structure (e.g., railing) that results in the functional performance of the implant 
no longer being acceptable and/or that results in adverse events.  
 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04  
Page 51 of 90 
  
 All suspected device deficiencies, malfunctions or failures for the study device will be 
documented on the appropriate eCRF.  In the event of a suspected device deficiency or 
other device issue, the device shall be returned to the Sponsor to the extent possible for 
analysis.  Investigational devices shall be returned to the Study Sponsor a s described in 
Section 10.4.  
12.2 REPORTING  PROCEDURE  
Study patient s will be carefully monitored during the clinical study for  any possible 
adverse event. All  adverse event s will be fully investigated by [CONTACT_737]. 
Appropriate treatment for the patient  will be initiated while the study follow up 
continues. Adverse events will be followed until they are adequately resolved or 
explained.  
 
The Investigator will attempt to assess the involvement of the investigational device and 
/ or study procedure in the adverse ev ent. All observations and clinical findings, including 
the nature or the seriousness , will be document ed on the appropriate case report f orm 
(CRF) .  The investigator will classify the adverse events ( AEs) based on the definitions in 
section 12. 3 
 
Adverse events will be assessed by [CONTACT_688739] 2.7/3 revision 3 : 
 
Not related:   Relationship to the device or procedures can be excluded when:  
• The event is not a known side effect of the product category the device belongs 
to or of similar devices and procedures  
• The event has no temporal relationship with the use of the investigatio nal device 
or the procedures  
• The serious event does not follow a known response pattern to the medical device 
(if the response pattern is previously known) and is biologically implausible  
• The discontinuation of medical device application or the reduction o f the level of 
activation/exposure - when clinically feasible – and reintroduction of its use (or 
increase of the level of activation/exposure), do not impact on the serious event  
• The event involves a body -site or an organ not expected to be affected by [CONTACT_3433] e 
device or procedure  
• The serious event can be attributed to another cause (e.g. an underlying or 
concurrent illness/ clinical condition, an effect of another device, drug, treatment 
or other risk factors)  
• Harms to the subject are not clearly due to use er ror 
• In order to establish the non -relatedness, not all the criteria listed above might be 
met at the same time, depending on the type of device/procedures and the 
serious event  

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04  
Page 52 of 90 
  
 Unlikely:  The relationship with the use of the device seems not relevant and/or  the event 
can be reasonably explained by [CONTACT_5748], but additional information may be 
obtained.  
 
Possible:   The relationship with the use of the investigational device is weak but cannot 
be ruled out completely. Alternative causes are also possible (e .g. an underlying or 
concurrent illness/ clinical condition or/and an effect of another device, drug or 
treatment). Cases were relatedness cannot be assessed or no information has been 
obtained should also be classified as possible.  
Probable:  The relations hip with the use of the investigational device seems relevant 
and/or the event cannot reasonably be explained by [CONTACT_5748], but additional 
information may be obtained.  
 
Causal Relationship: The serious event is associated with the investigational devic e or 
with procedures beyond reasonable doubt when:  
• The event is a known side effect of the product category the device belongs to or 
of similar devices and procedures  
• The event has a temporal relationship with investigational device use/application 
or procedures  
• The event involves a body -site or organ that the investigational device or 
procedures are applied to or have an effect on  
• The serious event follows a known response pattern to the medical device (if the 
response pattern is pre viously known)  
• The discontinuation of medical device application (or reduction of the level of 
activation/exposure) and reintroduction of its use (or increase of the level of 
activation/exposure), impact on the serious event (when  
clinically feasible)  
• Othe r possible causes (e.g. an underlying or concurrent illness/ clinical condition 
or/and an effect of another device, drug or treatment) have been adequately 
ruled out  
• Harm to the subject is due to error in use  
 
In order to establish the relatedness, not all  the criteria listed above might be met at the 
same time, depending on the type of device/procedures and the serious event  
 
The Investigator will report any serious adverse event, anticipated or unanticipated, to 
the Study Sponsor  within three  (3) calendar  days  after first knowledge of the event.  
Unanticipated Adverse Device Effects (UADE) should be reported to the Sponsor within 
three  (3) calendar  days. Notification to the Study Sponsor prefer entially  be made via the 
adverse event form in the electronic database (EDC).  

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04  
Page 53 of 90 
  
 In the event that the EDC system is not accessible, the Sponsor may be notified initially 
by [CONTACT_688740], the following 
minimal information should be provided:  
 
• Study site  number  
• Patient ID  
• Date of event  
• Aware date  
• Adverse event description  
• Causal relationship to device and implant procedure  
The AE eCRF should be completed  as soon as possible thereafter.  
 
The Investigator (or designee) shall provide source documents related to reported 
adverse event as requested by [CONTACT_474973].  
 
The Sponsor will evaluate all adverse events for reportability as an UADE in accordance 
with 21 CFR part 812.46(b ).  The Investigator and Sponsor will comply with repor ting 
requirements per 21 CFR part 812.150.  A Sponsor who conducts an evaluation of an UADE 
under 812.46(b) shall report the results of such evaluation to FDA and to all reviewing 
IRB’s and participating Investigators within [ADDRESS_934443]  and / or National Regulatory Agency in accordance with the applicable 
requirements.  
 
Finally, the Investigator should follow all unresolved adverse events until the events are 
resolved  or otherwise explained , or the patient is lost to follow -up or has wit hdrawn 
consent . 
12.3 FINDINGS EXPECTED TO OCCUR WITH TREATMENT OF TRICUSPID  
REGURGITATION AND/OR INTERVENTIONAL CARDIAC PROCEDURES THAT DO 
NOT REQUIRE REPORTING TO THE SPONSOR  
For purposes of this study, the following findings are not considered adverse events 
requiring reporting to the Sponsor. These findings are normally expected to occur in 
association with treatment of tricuspid  regurgitation, and/or are associated with 
customary, standard care of patients undergoing interventional cardiovascular 
interventio ns: 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04  
Page 54 of 90 
  
 • Post -procedure pain (within 48 hour of procedure) not requiring treatment or 
treated with non -opi[INVESTIGATOR_2438]  
• Emesis, nausea, or headache (within 48 hours of procedure) associated with 
anesthesia  
• Out of range (outside the standard laboratory normal value) or “abnormal” lab 
values (including electrolyte imbalance) that are not clinically significant and do 
not require correction.  
Note: Abnormal lab values that roll up to a diagnosis should not be reported as 
separate A Es (e.g. elevated BNP in patient with hear t failure; increased K+ in 
patient with renal insufficiency; elevated white blood count without signs or 
symptoms of infection)  
• Low grade temperature increase without signs and symptoms of infection  
• Minor, localized tenderness, swelling, induration, oozing, etc. at access site(s)  
• Sinus bradycardia or tachycardia that does not require treatment or intervention  
• Systolic or diastolic blood pressure changes that do not require treatment or 
intervention  
• The need for insulin in a diabetic patien t in the post op period  
This listing of events is intended to provide guidance to the investigational sites for the 
purpose of adverse event reporting.   The Investigator should utilize his/her clinical 
judgment in evaluating adverse experiences, and may decide that the above events 
should be reported as adverse events.  
12.4 DEATHS AND EXPLANTS  
12.4.1  PATIENT  DEATHS  
Patient death occurring during the study  should be reported to the Sponsor or designee 
within one (1) business day  of Investigator’s knowledge of the death.  The Adverse Event 
that resulted in death should be entered in the database on the Adverse Event form 
within one (1) business day  and include a brief description of the relevant clinical 
information leading to the death of the patie nt. In the event of patient  death, every effort 
should be made to obtain a copy of the autopsy report and/or death summary.  
Information on the cause of death and its relationship to the investigational  device or 
study procedure will be determined by [CONTACT_737] . Copi[INVESTIGATOR_50279], if 
available, and/or a death summary are to be forwarded  to the Study Sponsor.  
 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #[ADDRESS_934444] -operative period, every effort should be 
made to obtain a copy of the explant procedure report, as applicable.  Information on the 
cause of explant and its relationship to the stud y device will be determined by [CONTACT_3786]. Copi[INVESTIGATOR_688712], if available, are to be sent to the Study Sponsor. 
Explanted study devices during this period should  be returned to Study Sponsor for 
analysis.  Investigational devices shall be return ed to the Study Sponsor  as described in 
Section 10.4. 
13 STATISTICAL ANALYSIS  
13.1 SAMPLE SIZE  
This clinical study will enroll 60 patient s. This sample size was established based on typi[INVESTIGATOR_688713].  
13.2 ANALYSIS POPULATION  
The analysis population  will be grouped into three analysis cohorts that in total comprise 
all patient s in whom the study procedure has been attempted (vascular access obtained)  
in this study .  The analysis cohorts are  defined below :  
 
• Intent -to-treat population   
The intention -to-treat (ITT) population includes all patients who signed 
informed consent, met eligibility criteria, and in whom the study procedure 
has been attempted ( i.e. at least skin incision  to introduce the FORMA 
System ). 
 
• As-treated  population  
The as -treated population  is a subset of ITT population and  includes all 
patients in whom the study device is implanted and remains in position at the 
time of the patient’s exit from the procedure room . 
 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04  
Page 56 of 90 
  
 • Per-protocol population  
The per -protocol (PP) population is a subset of as -treated (implanted) 
population in wh om there are no major protocol deviations.  
 
The as -treated population will be the primary analysis population for performance and 
safety assessment.  The ITT population will be used for device success, and  additional 
safety analysis. Additional analyses of performance and safety data  using the PP 
population will also be performed.  
  
13.3 DEVICE  SUCCESS  ENDPOINT  ANALYSIS  
The device success  endpoint will be summarized by [CONTACT_688741]-treated  cohort.  The endpoint will be assessed at the 1 month, 6 -month, 1 year, 2 -
year and 3 -year follow -up intervals.    
 
In addition to the device success analysis, hemodynamic performance data will be 
obtained at the following time points: baseline, [ADDRESS_934445] deviation will be calculated for the 
continuous echo variables as well as the change from baseline for each variable.  
13.4 PROCEDURE  SUCCESS  ENDPOINT  ANALYSIS  
The procedure success  endpoint will be summarized by [CONTACT_688742]-treated  cohort.  The endpoint will be assessed at the index procedure  hospi[INVESTIGATOR_426634] .  
13.5 CLINICAL  SUCCESS  ENDPOINT  ANALYSIS  
The clinical  success endpoint will be summarized by [CONTACT_688743]-
treated  cohort .  The endpoint will be assessed at the 1 month  follow -up interval.   
 
Patient specific functional status (NYHA Class) , exercise capacity (6MWT) , blood test 
parameters , and  quality of life  (SF-12 and KCCQ) metrics will be assessed at baseline,  1 
month , 6 months and annually up to 3 years.  The distribution (numbers of patient s and 
percentages) in the various NYHA classes will be tabulated at baseline, 1 month , 6 months  
and annually up to 3 years.   Patient s that are missing a baseline or follow up values will 
be excluded from the analysis.  Patient s that undergo any type of rep air or replacement 
procedure for the tricuspid valve will be excluded from these analyses at the time of the 
reintervention and summarized in a table.  
 
Rehosptilization rates will be assessed at 1 month , 6 months and annually up to 3 years.  

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #[ADDRESS_934446] with the study  site throughout 
the duration of the study to provide any needed materials, (i.e.  study forms , etc. ) answer 
any questions and ensure that proper staffing levels are being maintained by [CONTACT_3786].  The study monitor will be responsible for verifying  that patient s have signed 
the informed consent as required by [CONTACT_19124], reviewing the data recorded on the 
eCRFs and visiting the study  site periodically to observe study progress and compliance 
with the study  protocol and regulations applicable to this clin ical study.  
 
Monitoring visits will be scheduled throughout the  duration of the  clinical study between 
the monitor and the  Investigator at a mutually convenient and available time.  These visits 
will assure that the facilities are still acceptable, the stu dy protoco l is being followed, the 
IRB and FDA have been notified of approved protocol changes as required, complete 
records are being maintained, appropriate timely reports have been made to the Study 
Sponsor and the IRB, device and device inventory are controlled and the Investigator is 
carrying out  all agreed activities.  Any personnel changes must be reported to the study 
monitor immediately and a training program scheduled and documented.   
14.2 MONITORING PLAN 
Prior to patient  enrollment, an initiation visit will be completed at the study site to ensure  
the following:   
 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #[ADDRESS_934447] been obtained and 
documented,  
2. The Investigator (s) and study personnel are appropriately trained and clearly 
understand the study,  
3. The Investigator (s) and study personnel accept the obligations incurred in 
undertaking this clinical study , 
4. The Del egation of Authority form has been completed properly.  
 
Periodic monitoring visits will be made at the enrolling study  site in accordance with site 
enrollment rates. The s tudy site should be visited a minimum of twice  per year  by [CONTACT_119645].  
 
Upon termination or conclusion of the study, the study monitor will perform a close -out 
visit.   
14.[ADDRESS_934448] the life or physical well -being of a patien t in an emergency.  Such approval shall 
be documented in writing and maintained in study files.  Prior approval is generally not 
expected in situations where unforeseen circumstances are beyond the Investigator’s 
control, (e.g. patient  did not attend schedu led follow -up visit, etc.) however the event is 
still considered a deviation.   
 
Deviations shall be reported to the Study Sponsor regardless of whether medically 
justifiable, pre -approved by [CONTACT_1034], or taken to protect the patient  in an emergency.  
Patient  specific and  non-patient  specific deviations, (e.g. unauthorized use of an 
investigational device outside the study, unauthorized use of an investigational device by 
a physician who is not listed in the Clinical Study Agreement  etc.) will be reporte d in 
writing.  Patient  specific deviation information can be recorded directly on the Protocol 
Deviation eCRF and non -patient  specific deviations will be recorded in writing.  
Investigators will also adhere  to procedures for reporting study deviations to the ir IRB in 
accordance with their specific reporting policies and procedures.  
 
For reporting purposes, deviations are classified as major or minor:  
 
1. Major deviation : 
a. Any deviation from patient  inclusion and exclusion criteria ;  
b. Any deviation from patient  informed consent procedures ; 
c. Unauthorized use of an investigational device outside the study ; 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04  
Page 59 of 90 
  
 d. Unauthorized use of an investigational device by a physician who is not 
indentified  in the Delegation of Authority Log  
 
2. Minor deviation :   
a. Deviation from a protocol requirement  such as incomplete/inadequate 
patient  testing procedures ;  
b. Follow -up performed outside specified time windows.  
14.4 COMMUNICATION PROCEDURES  
During the course of the study, all correspondence (letters, telephone call, emails and 
faxes) regarding the study must be maintained in the study binder provided by  [CONTACT_28829].  This binder must be made available for monitoring visits or audits.  
15 DATA MONITORING COMMITTEE  
The Study Sponsor with an independent  Data Monitoring Committee (DMC) will monitor 
all safety data.  The DMC  will consist of a minimum of 3 members, all members being 
physicians ; one cardiothoracic surgeon , one interventional cardiologist  and one 
cardiologist .   
 
DMC activities, including stoppi[INVESTIGATOR_004], will be defined in DMC Charter . 
 
[ADDRESS_934449] and of clinical studie s; they also represent sound research practice.  It 
is the responsibilities of the Investigator (s) to comply with the requirements set forth in 
their country specifi c regulations.   
 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04  
Page 60 of 90 
  
 Table 13 – Applicable Regulations and Guidelines  
Region  Regulation / Guideline  
[LOCATION_002]  - 21 CFR 50 – Protection of Human Patient s 
- 21 CFR 56 – Institutional Review Boards  
- 21 CFR 54 – Financial Disclosure by [CONTACT_6230]  
- 21 CFR 58 – Good Laboratory Practice for Nonclinical Laboratory 
Studies  
- 21 CFR 812: Investigational Device Exemptions  
- 21 CFR 820 – Quality System Regulation  
- EN ISO [ZIP_CODE]:2012 Medical Devices – Quality Management 
Systems – Requirements for Regulatory Purposes  
- ISO [ZIP_CODE]:2011 I (Clinical Investigatio n of Medical Devices for 
Human Patient s 
- ISO [ZIP_CODE]:20 12 (Application of risk management to medical 
devices)  
 
Furthermore, the Investigator (s) must comply with the requirements  of the Declaration 
of Helsinki (2008) and with of ICH E6 GCP or with laws of the foreign country, whichever 
will afford greater protection to the patient  screened for participation in the clinical study 
and patient s who participate in the study.  
16.[ADDRESS_934450] been 
removed from the study  site.  Patient  identifiers include, but are not limited to: patient ’s 
name, social securit y number or equivalent, and medical / hospi[INVESTIGATOR_7965].  All study 
documents for the clinical study will identify the patient  by a patient  study identification 
number assigned by [CONTACT_688744] ’s initials.  
16.[ADDRESS_934451] of the clinical study and for the safety and 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #[ADDRESS_934452].  
 
The Investigator is responsible for obtaining and maintaining IRB approval for the study 
at his/her s tudy site.   
 
If there is a change or addition of  an Investigator, an amended Clinical Study Agreement 
must be completed promptly.  
16.2.[ADDRESS_934453] be kept on file by [CONTACT_737].  If the Investigator wishes to assi gn the 
responsibility of maintaining the study files to someone else or move them to another 
location, he/she should consult with the Study  Sponsor in writing regarding  the change.   
Upon Study completion , the study files must be maintained in a known location for  a 
period in accordance with local regulatory requirements.   
16.2.3   INVESTIGATOR REPORTS  
 
 
 
  
   
   
    
  
 
 
  
   
  
   
  
 
 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #[ADDRESS_934454] of the study, including assurance that the study meets the 
regulatory requirements o f the pertinent regulatory agencies .   
 
In addition, the Study Sponsor  declares that no employee/affiliate of the Sponsor or 
Investigator will be included or encouraged to participate in this investigational study.  
 
The Study Sponsor  will inform the Investigator of any new information about the study 
that may affect the health, safety or welfare of the patient s or which may influence 
patient’s decision to continue participating in the study . 
16.4 SELECTION OF INVESTIGATORS   
 
 
 
 
16.4.1  MONITORING THE STUDY  
The Study Sponsor  will ensure compliance with the signed clinical agreement, the 
protocol (investigational plan), the requirements of applicable regulations and guidelines 
(see section 16.1) and any conditions of study approval by [CONTACT_688745].  
Edwards will conduct an immediate investigation of any unanticipated adverse device 
effects (UADE) and if an event is found to present an unreasonable risk to study patient s, 
the Stud y Sponsor  will inform Investigators , IRBs, and regulatory bodies  as required . 
16.4.[ADDRESS_934455] party.  
16.4.3  SPONSOR REPORTS  
 
 

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04  
Page 63 of 90 
  
  
-  
 
 
   
  
     
  
 
 
  
 
  
   
  
 
 
  
 
   
  
 
 
  
 
16.5 STUDY CHANGES  
Changes in the protocol may be made only by [CONTACT_688746] S ponsor, the regulatory agency and IRB.  As appropriate, the Study Sponsor  will 
submit protocol  amendments  to the pertinent regulatory agencies and Investigators  to 
obtain IRB approval  prior to implementation . 
16.6  STUDY COMPLETION OR TERMINATION AND CLOSE -OUT 
The I nvestigator will be notified in writing upon termination/conclusion of the study.  
Edwards Lifescien ces retains the right to suspend or terminate this clinical study  at any 
time.  
 
Safety and review committees associated with the study may recommend termination 
should safety concerns warrant such action as described in Section 15. 
 
All study patient s enrolled up to the point of study termination , will  continue to be 
followed as per protocol requirements.  

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04  
Page 64 of 90 
  
 16.7 AUDITS AND INSPECTIONS  
In the event that audits are initiated by [CONTACT_71392] S ponsor or national/international 
regulatory authorities, the Investigator shall allow access to the original medical records 
and provide all requested information , as applicable . 
16.8 PUBLICATION POLICY  
 
 
 
 
   
 
  

Edwards FORMA Tricuspid Transcatheter System  Early Feasibility  Study   
 
Version K  
 Study #[ADDRESS_934456] of tricuspid regurgitation 
on long -term survival.  Journal of the American College of Cardiology, 2004. 
43(3): p. 405 -409.  
2. Nishimura, R.A., et al., 2014 AHA/ACC guideline for the management of 
patients wi th valvular heart disease: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines.  J 
Thorac Cardiovasc Surg, 2014. 148(1): p. e1 -e132.  
3. Dreyfus, G.D., S.G. Raja, and K.M.J. Chan, Tricuspid leaflet augm entation to 
address severe tethering in functional tricuspid regurgitation.  European 
Journal of Cardio -Thoracic Surgery, 2008. 34(4): p. 908 -910.  
4. Benedetto, U., et al., Prophylactic tricuspid annuloplasty in patients with 
dilated tricuspid annulus under going mitral valve surgery.  The Journal of 
thoracic and cardiovascular surgery, 2012. 143(3): p. 632 -8. 
5. Raja, S.G. and G.D. Dreyfus, Surgery for functional tricuspid regurgitation: 
current techniques, outcomes and emerging concepts.  Expert Rev 
Cardiovas c Ther, 2009. 7(1): p. 73 -84. 
6. Chang, B.C., et al., Long -term clinical results of tricuspid valve replacement.  
Annals of Thoracic Surgery, 2006. 81(4): p. 1317 -1324.  
7. Vahanian, A., et al., Guidelines on the management of valvular heart 
disease (version  2012): the Joint Task Force on the Management of 
Valvular Heart Disease of the European Society of Cardiology (ESC) and the 
European Association for Cardio -Thoracic Surgery (EACTS).  Eur J 
Cardiothorac Surg, 2012. 42(4): p. S1 -44. 
[ADDRESS_934457] -in-man experince of 
a novel transcatheter repair system for treating severe tricuspid 
regurgitation . J Am Coll Cardiol. 2015;66:2475 -2483  
9          Perlman, G., et a l., Transcatheter Tricuspid Valve Repair With a N ew 
Transcatheter Coaptation System for the Treatment of Severe Tricuspid 
Regurgitation . Journal of American College of Cardiology: Cardiovascular 
Interventions, 2017.  10 (19) p. 1994 -2003.  
10.       Abbas, A.E., et a l., A simple method for noninvasive estimation of 
pulmonary vascular resistance .  Journal of American College of Cardiology, 
2003. 41(6): p. 1021 -7. 
 
 
 

Edwards FORMA  Tricuspid Transcatheter  System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04 
Page 66 of 90 
  
 18 DEFINITIONS  
 
Access Site  Access site defined as any location (venous) traversed by a 
guidewire, a catheter or a sheath (including the subclavian or 
axillary vein)  
ACT Activated clotting time  
Acute Kidney Injury  
(AKI)  Refer to VARC -[ADDRESS_934458] 
(ADE)  Refer to ISO [ZIP_CODE] definition  
Adverse Event (AE)  Refer to ISO [ZIP_CODE] definition  
Bleeding  (VARC -2) Life Threatening or Disabling Bleeding  
• Fatal bleeding (BARC type 5) OR  
• Bleeding in a critical organ, such as intracranial, intraspi[INVESTIGATOR_1304], 
intraocular, or pericardial necessitating pericardiocentesis, 
or intramuscular with compartment syndrome (BARC type 
3b and 3c) OR  
• Bleeding causing hypovolaemic shock or severe hypotension 
requiring vasopressors or surgery (BARC type 3b) OR  
• Overt source of bleeding with drop in haemoglobin >5 g/dL 
or whole blood or packed red blood cells (RBCs) transfusion 
>4 units* (BARC type 3b)  
Major Bleeding  
• Overt  bleeding either associated with a drop in the 
hemoglobin level of at least 3.0 g/dl or requiring transfusion 
of two or three units of whole blood/RBC, or causing 
hospi[INVESTIGATOR_384663], or requiring surgery 
AND  
• Does not meet criteria of life -threatening or disabling 
bleeding  
Minor Bleeding  
Any bleeding worthy of clinical mention (e.g. access site 
hematoma) that does not qualify as life -threatening, disabling, 
or major  
Cardiac Tamponade  Pressure on the heart that occurs when blood or fluid builds up 
in the space between the heart muscle (myocardium) and 
the outer covering sac of the heart (pericardium).   

Edwards FORMA  Tricuspid Transcatheter  System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04 
Page 67 of 90 
  
 Cardiovascular 
Mortality  Refer to VARC -2 definition  
Cerebrovascular 
Accident (CVA)  See “Stroke”  
Clinical Success  Clinical success: procedural success without MAEs at 30 days.  
Death  See “Cardiovascular Mortality”  
Device Deficiency  Refer to ISO [ADDRESS_934459].  
Device Embolization  Refer to ISO 5840 -3 definition  
Device Malfunction  Refer to ISO [ZIP_CODE] definition  
Device Migration  Refer to ISO 5840 -3 definition  
Device Success  Device success: device is deployed as intended and the delivery 
system is successfully retrieved as intended at the time of the 
patient’s exit from the cardiac catheterization laboratory.  
eGFR Estimated glomerular filtration rate  
Embolism  Free flowing blood clot or lesion material that is located in the 
systemic or pulmonary circulation.  
 
A peripheral embolic event is an operative, autopsy or clinically 
documented embolus that produces symptoms from complete 
or partial obstruction or a periphera l (noncerebral) artery.   

Edwards FORMA  Tricuspid Transcatheter  System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04 
Page 68 of 90 
  
 Emergency Cardiac 
Surgery  Emergent Salvage :  The patient is undergoing CPR en route to the 
operating room or prior to anesthesia induction  
 
Emergent:   The patient’s clinical status includes any of the 
following:  
1. Ischemic dysfunction of any of the following:  
a. ongoing ischemia including rest angina despi[INVESTIGATOR_688714] (medical and/or IABP);  
b. Acute Evolving Myocardial Infarction within 24 hours 
before surgery or  
c. pulmonary edema requiring intubation  
2. Mechanical dysfun ction (either of the following):  
a. shock with circulatory support; or  
b. shock without circulatory support.  
 
Urgent : All of the following conditions are met:  
• Not elective status  
• Not emergent status  
• Procedure required during same hospi[INVESTIGATOR_688715]  
• Worsening, sudden chest pain, CHF, acute myocardial 
infarction (AMI), anatomy, IABP, unstable angina with 
intravenous (IV) nitroglycerin (NTG) or rest angina may be 
included.  
 
Elective:   The patient’s cardiac function has been stable in the 
days or weeks prior to the operation. The procedure can be 
deferred without increased risk of compromised cardiac 
outcome.  
Endocarditis  An inflammation of the inside lining of the heart chambers and 
heart valves (endocardium).  Endocarditis can involve the heart 
muscle, heart valves, or lining of the heart.  
Enrollment  Patient  enrollment in this clinical study is established when a 
patient  has signed the informed consent form agreeing to 
participate in the study a nd has been deemed eligible for study 
participation by [CONTACT_688747].   
Explant  Removal of the study device after completion of the implant 
procedure for any reason.  

Edwards FORMA  Tricuspid Transcatheter  System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04 
Page 69 of 90 
  
 Heart Failure  Heart Failure - A progressive condition that involves loss of 
pumpi[INVESTIGATOR_688716] (heart muscle weakens and 
gradually loses its ability to pump enough blood through the 
body), generally accompanied by [CONTACT_407814], especially the lungs.  
 
Heart Failure Hospi[INVESTIGATOR_059] - An unplanned hospi[INVESTIGATOR_688717] (i.e., where the admission 
date and the discharge date are different) that includes 
increased signs and/or symptoms of worsening heart failure and 
requires the administration or augme ntation of existing heart 
failure therapy.  
 
Severe Heart Failure – See NYHA Class IV  
HEART Team  (local)  The local ‘HEART Team', for the purpose of this study, must 
include a minimum of one Cardiologist, and one Cardiac Surgeon . 
Hemolysis  
(Device Hemolysis)  Rupturing of red blood cells (erythrocytes) and the release of 
their contents (cytoplasm) into surrounding fluid s. 
 
Device hemolysis is defined as hemolysis in or near the 
investigational device that interferes with the function of the 
device.  Device hemolysis related thrombus may be confirmed by 
[CONTACT_407815], autopsy, or diagnostically by [CONTACT_688748], angiography, or magnetic resonance imaging.  
Implant procedure  Placement of the investigational device in the tricuspid valve 
regurgitant orifice.  
Infection  Known infection requiring intravenous antibiotics for other than 
prophylaxis, a nd/or extended hospi[INVESTIGATOR_059].  
INR International normalized ratio  
KCCQ  Kansas City Cardiomyopathy Questionnaire is a health -related 
quality -of-life measure for patients with congestive heart failure.  
LVEF  Left ventricular ejection fraction  
MAE  Major adverse event defined as cardiovascular mortality, 
myocardial infarction, new need for renal replacement therapy, 
severe bleeding and re -intervention for study device related 
complications  
Malfunction  Refer to ISO [ZIP_CODE] definition  
Mortality  See “Cardiovascular Mortality”  
Myocardial Infarction  Refer to VARC -2 definition  

Edwards FORMA  Tricuspid Transcatheter  System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04 
Page 70 of 90 
  
 [LOCATION_001] Heart 
Association 
Classification (NYHA 
Class)  Class I : Patients with cardiac disease but without resulting 
limitations of physical activity.  
Class II :      Patients with cardiac disease resulting in slight 
limitation of physical activity.  Patients are comfortable at rest.  
Ordinary physical activity results in fatigue, palpi[INVESTIGATOR_332], dyspnea, 
or anginal pain.  
Class III :     Patients with cardiac disease resulting in marked 
limitation of physical activity.  They are comfortable at rest.  Less 
than ordinary physical activity causes fatigue, palpi[INVESTIGATOR_688718], o r anginal pain.  
Class IV :     Patients with cardiac disease resulting in inability to 
carry on any physical activity without discomfort.  Symptoms of 
cardiac insufficiency or of the anginal syndrome may be present 
even at rest.  If any physical activity is undertaken, discomfort is 
increased.  
Nonstructural 
Dysfunction  Abnormality extrinsic to the repair device that results in valve 
dysfunction (stenosis, regurgitation or both)   
Pacemaker 
Dependency  Continuous ventricular stimulation without any  pacemaker 
inhibition by [CONTACT_688749] 180 days.  
Patient  A person with the disease (tricuspid regurgitation) being 
screened to participate in the clinical study.  
Peripheral 
Thromboembolic 
Event  See “Embolism”  
Pre-Existing Condition  A pre -existing condition is one that is present at the start of study 
treatment.  
Procedural Success  Procedural success: device success with evidence of TR reduction 
as evidenced by a relative reduction in EROA of ≥ 30% from 
baseline to discharge and without the need for a surgical or 
percutaneous intervention prior to hospi[INVESTIGATOR_2345].  
Prosthesis  An artificial substitute  
QoL Quality of Life  
Reintervention  Any intervention (surgical or transcatheter) on the previously 
implanted study device ( repair, alter ation  or replace ment)  or 
study procedure access site post -implant procedure . 
Renal Failure  See “Acute Kidney Injury (AKI)”  
Screen Failure  A patient who has signed the consent but, does not meet the 
inclusion criteria or who meets at least one of the exclusion 
criteria.  

Edwards FORMA  Tricuspid Transcatheter  System  Early Feasibility  Study   
 
Version K  
 Study #[ADDRESS_934460] (SADE)  Refer to ISO [ZIP_CODE] definition  
Serious Adverse Event 
(SAE)  Refer to ISO [ZIP_CODE] definition  
Severe Bleeding  Severe bleeding is a major ,  life-threatening /disabling  or fatal 
bleeding , as defined by [CONTACT_44248] -2. 
SF-12 A short survey  with  12 questions  that results  in two scales  of  
mental  and physical  functioning  and overall  health related  
quality  of life. 
Six (6) MWT  Six minute walk test  
Stroke/TIA  Refer to VARC -2 definition  
Patient   Refer to ISO [ZIP_CODE] definition  
Patient  Withdrawal  A patient  who decides not to participate in the study after  
signing an informed consent form and being enrolled.  
Thromboembolic 
Event  See “embolism”  
Thrombus  
(Device Thrombosis)  An aggregation of platelet, fibrin, clotting factors, and other 
cellular elements exclusive of infection.  
 
Device thrombosis is defined as any thrombus in the absence of 
infection attached to or near the investigational device that 
interferes with functio n of the device.  An investigational device 
related thrombus may be confirmed by [CONTACT_407815], autopsy, or 
diagnostically by [CONTACT_407816], 
angiocardiography, or magnetic resonance imaging.  
Tricuspid  
Regurgitation  Tricuspid Regurgitation ( TR), tricuspid insufficiency or tricuspid 
incompetence describes a condition in which blood flow through 
the tricuspid valve flows in the incorrect direction during part of 
the cardiac cycle.  
Unanticipated Serious 
Adverse Device Effect 
([LOCATION_003]DE)  Refer to ISO [ZIP_CODE] definition  
Valvular Leak  
 
(See Also 
“Nonstructural 
Dysfunction”)  Any evidence of leakage of blood through the native valve 
leaflets and around the investigational device. Diagnosis of 
valvular leak may be obtained from echo; however definitive  
diagnosis is obtained at reoperation, explant, or autopsy.  
Withdrawal by 
[CONTACT_10670]  A patient  who consents to participate in the study and is  
enrolled but is withdrawn by [CONTACT_737].  
 
 
 

Edwards FORMA  Tricuspid Transcatheter  System  Early Feasibility  Study   
 
Version K  
 Study #2014 -04 
Page 72 of 90 
  
 19 APPENDIX A - SAMPLE  INFORMED CONSENT FORM  
 
 
  
